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ELEVATING ENDOGENOUS CANNABINOIDS REDUCES OPIOID WITHDRAWAL 
IN MICE 
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Director: Dr. Aron Lichtman, Ph.D., Professor, Department of Pharmacology & Toxicology 
Virginia Commonwealth University 
Richmond, Virginia 


9-tetrahydrocannbinol (THC), the primary active constituent of Cannabis sativa, has 
long been known to reduce opioid withdrawal symptoms. Although THC produces most of its 
pharmacological actions through the activation of CB1 and CB2 cannabinoid receptors, the role 
these receptors play in reducing opioid withdrawal symptoms remains unknown. The 
endogenous cannabinoids, N-arachidonoylethanolamine (anandamide; AEA) and 2-
arachidonylglycerol (2-AG), activate both cannabinoid receptors, but are rapidly metabolized by 
fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. The 
objective of this dissertation was to test whether increasing AEA or 2-AG, via inhibition of their 
respective hydrolytic enzymes, reduces morphine withdrawal symptoms in in vivo and in vitro 
models of opiate dependence. Morphine-dependent ICR mice subjected to acute naloxone 
challenge or abrupt withdrawal (via pellet removal) reliably displayed a profound withdrawal 
syndrome, consisting of jumping, paw tremors, head shakes, diarrhea, and weight loss. THC 
and the MAGL inhibitor, JZL184 dose-dependently reduced the intensity of precipitated 
withdrawal measures through the activation of CB1 receptors.  The FAAH inhibitor, PF-3845, 
reduced the intensity of a subset of precipitated signs through the activation of CB1 receptors, 
xv 
 
but did not ameliorate the incidence of diarrhea or weight loss. In the next set of experiments, 
MAGL inhibition dose-dependently reduced the intensity of all spontaneous withdrawal signs 
(i.e jumps, paw flutters, head shakes, weight loss and diarrhea) in a CB1 receptor dependent 
manner. However, FAAH inhibition reduced the intensity of head shakes and paw flutters, but 
did not affect other signs. Strikingly, a combination of low-dose JZL184 and high-dose PF-3845 
reduced abrupt withdrawal signs in a manner similar to complete MAGL inhibition, which 
suggests potential therapeutic advantages of dual enzyme inhibition. This combination elevated 
appropriate eCB levels and caused moderate CB1 receptor desensitization, but did not affect 
receptor number in whole brain. Since MAGL, but not FAAH inhibition, blocked diarrhea 
during opioid withdrawal in vivo, we investigated whether inhibitors of each enzyme would 
differentially attenuate naloxone-precipitated contractions and secretion in morphine-dependent 
ilea in vitro. Both enzyme inhibitors attenuated the intensity of naloxone-induced contractions, 
and blocked naloxone-precipitated hypersecretion. Although these models offer useful tools for 
investigating in vitro end-points of withdrawal, further research is needed to elucidate the anti-
diarrheal mechanism of these inhibitors. If targeting endocannabinoid catabolic enzymes is 
indeed a viable approach to treat other abuse disorders, it is important to know whether these 
inhibitors would themselves have abuse or dependence liability. In the final series of 
experiments we tested whether prolonged elevation of endocannabinoid leads to the 
development of cannabinoid dependence, based on the occurrence of somatic withdrawal signs 
upon challenge with rimonabant, a CB1 receptor antagonist. Repeated treatment with high 
doses, but not low doses, of JZL184 led to cannabinoid dependence. These results indicate that 
the strategy of increasing endogenous cannabinoids through the inhibition of their catabolic 
enzymes represents a promising approach to ameliorate opioid withdrawal symptoms. 
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Chapter 1: Introduction 
 Opiate Dependence 
Opioids have been used for centuries for their acute analgesic, antitussive, antidiarrheal 
and euphoric effects.  Importantly, opiates are the mainstay in the management of chronic pain 
conditions. Tolerance manifests clinically as the need for increasing drug doses over time to 
produce equivalent therapeutic effects and is demonstrated in the laboratory as decreased 
potency and/or efficacy of a drug to produce its acute pharmacological effects. Dependence is 
revealed upon cessation of opioid treatment and presents as a withdrawal syndrome that 
includes both physiological and motivational signs. The risk of opiate dependence from chronic 
use of prescription analgesics and illicit substances remains high, despite growing awareness of 
the potential for abuse and/or misuse.  An important component of opiate dependence is 
withdrawal, an aversive syndrome that occurs on cessation of drug use and contributes to drug 
maintenance; thus thwarting efforts for rehabilitation. In humans, spontaneous opioid 
withdrawal occurs soon after the last drug use and is characterized by a range of aversive 
effects, including behavioral (e.g., anxiety, shakes), gastrointestinal (e.g., diarrhea, emesis, 
dehydration), and other physiological effects (e.g., hypertension, tachycardia, and body aches) 
(DSM-IV).  Current treatment for opiate withdrawal includes maintenance therapy with 
replacement opiates, such as methadone or buprenorphine. However, these opioid agonists also 
generate physical dependence.  For example, abrupt discontinuation from methadone can trigger 
a withdrawal syndrome albeit less severe, but longer lasting than that resulting from heroin 
(Dyer et al., 1999).  Similarly, physical dependence has been reported after chronic 
buprenorphine treatment (Kuhlman et al., 1998).  Given the limitations of these extant 
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replacement therapies, there is need for non-opioid drug therapies with reduced associated 
addiction potential. 
Natural Opiates and Opioid Receptors 
The naturally occurring opiates such as morphine and codeine are obtained from the poppy 
plant Papaver somniferum. The endogenous opioid system consists of several families of 
related neuropeptides and the three primary opioid receptor subtypes mu, delta and kappa. The 
opioid peptides as well as natural and synthetic opioids act via interactions with these receptors 
(Akil et al., 1984; Thompson et al., 1993; Mansour et al., 1995). Opioid receptors were first 
identified in 1973 using stereospecific radioligand binding (Pert and Snyder, 1973; Simon et al., 
1973; Terenius, 1973) and subsequently classified into three types, mu, delta and kappa, based 
on results of behavioral and bioassay studies (Martin et al., 1976; Lord et al., 1977). Further 
pharmacological characterization has revealed that mu opioid receptors mediate the effects of 
most clinically relevant opioids, such as morphine and heroin. Cloning of the opioid receptors 
confirmed the existence of mu (MOR), kappa (KOR) and delta (DOR) opioid receptors and 
confirmed their heptahelical structure (Evans et al., 1992; Kieffer et al., 1992; Chen et al., 
1993a; Chen et al., 1993b; Meng et al., 1993; Thompson et al., 1993). The generation of 
genetically altered (transgenic) mice lacking each of the opioid receptors has confirmed that 
MOR mediates the acute effects of most clinically relevant opioid drugs, such as analgesia, 
respiratory depression, locomotor stimulation and reinforcement, as well as chronic effects such 
as physiological withdrawal signs (Matthes et al., 1996; Sora et al., 1997; Loh et al., 1998; 
Becker et al., 2000). Heroin, a derivative of morphine, which is rapidly metabolized to 6-acetyl 
morphine and subsequently converted morphine, also acts primarily via MOR (Kitanaka et al., 
1998; Contarino et al., 2002).  
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Opioid Withdrawal 
 Dependence has been defined in DSM-IV as a maladaptive pattern of substance abuse 
including tolerance, withdrawal and a persistence desire to take the drug. Chronic use of opiates 
such as morphine and heroin leads to tolerance and dependence. Opiate drug abuse affects about 
0.6% of the US population annually (NSDUH) and repeated use of opiates leads to abstinence 
signs in addicts.  
 In the preclinical setting the opiate withdrawal syndrome is well characterized in 
rodents. Both the precipitated and spontaneous withdrawal model are commonly used to study 
opiate abstinence signs. Mice implanted with either a subcutaneous morphine pellet or exposed 
to repeated injections of increasing doses of morphine over a period of few days express overt 
quantifiable withdrawal signs upon administration of an opiate receptor antagonist, such as 
naloxone or abrupt cessation of morphine treatment (Way et al., 1969). The most commonly 
observed signs are jumps, paw tremors, head shakes, ptosis, teeth chattering, weight loss, and 
production of diarrhea.  
Neuroadaptive changes  
The most prominent neuroadaptive changes during morphine induced dependence include 
desensitization of MORs and upregulation of the cAMP pathway. The mitogen activated protein 
kinase (MAPK) pathway as well as Ca
2+
 signaling are also affected during morphine 
dependence with MAPK levels being modulated differentially by morphine treatment in 
different parts of the brain. The primary consequence of morphine withdrawal is 
‘superactivation’ of adenylyl cyclase (AC) and a subsequent overproduction of its downstream 
signaling molecule, cAMP. MOR signal transduction is Gα i/o coupled and chronic stimulation 
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of µOR by morphine leads to suppression of AC activity over a prolonged period of time. 
Concurrently, chronic morphine treatment also causes compensatory increases in activity of 
other subforms of AC thus restoring cAMP levels back to normal over the time course of 
chronic morphine treatment. When morphine treatment is abruptly halted or an opiate receptor 
antagonist such as naloxone is administered, causing disinhibition of AC activity and leading to 
massive overstimulation of AC coupled with increased AC production. This process leads to an 
overactivation of other downstream effectors of AC such as cAMP, PKA and transcription 
factors such as cAMP response element binding protein (CREB) (Nestler and Tallman, 1988; 
Guitart et al., 1992) (Fig. 1). CREB is also a downstream target of MAPK and Ca
2+ 
(Eitan et al., 
2003). Other cAMP actions during withdrawal include PKA-mediated enhanced GABAergic 
synaptic transmission in areas such as periaqueductal grey (PAG), ventral tegmental area 
(VTA), nucleus accumbens (N Acc.) and dorsal raphe. [For complete review see (Williams et 
al., 2001; Bailey and Connor, 2005; Sim-Selley, 2005)]  
 
Figure 1: Effects of acute and repeated exposure to opiates 
(Rt-left) Chronic morphine exposure leads to upregulation of AC and normalization of 
downstream signaling; Induction of withdrawal following chronic morphine exposure causes 
cAMP “overshoot” and increasing signaling of cAMP cascade resulting in expression of 
withdrawal signs 
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The cAMP superactivation and changes in CREB activation during withdrawal is most 
prominent in the LC as well as in N Acc, amygdala, DRN and VTA and is associated with the 
expression of external somatic signs during withdrawal (Widnell et al., 1994; Lane-Ladd et al., 
1997; Shaw-Lutchman et al., 2002; Han et al., 2006). CREB mediates the action of opioids on 
the expression of several genes in brain regions responsible for drug-seeking behavior and 
manifestation of withdrawal mediated changes in synaptic plasticity (Bilecki and Przewlocki, 
2000).  CREB binds to cAMP response element (CRE) in the promoter region of target genes 
and enhances the transcription of these genes. The phosphorylation of CREB is determined by 
cAMP in the LC and its function is regulated by the MOR. Further evidence for a role of CREB 
in mediating cellular adaptation in response to chronic opioid treatment is that LC neurons show 
decreased hyperexcitability following morphine withdrawal in CREB1(-/-) mice and in mice 
with a conditional mutation in CREB (Valverde et al., 2004). It is likely that adaptations to 
MORs in this brainstem region contribute to dependence and withdrawal. 
Cannabinoids 
Marijuana or Cannabis sativa has been used and cultivated for a variety of purposes as 
archaeological evidence dates back to 2350 B.C (Cannabinoids in nature and medicine, 2009). 
Δ9-tetrahydrocannabinol (THC) is the primary psychoactive constituent of marijuana. In 
addition, more than 70 other phytocannabinoids have been discovered (Elsohly and Slade, 
2005), and hundreds, if not thousands, of cannabinoids have been synthesized. The first 
constituent of marijuana was isolated by Roger Adams in 1940; which came to known as 
cannabidiol, lacking psychoactive properties and whose structure was later completely 
determined by Raphael Mechoulam (Adams et al., 1940; Mechoulam and Gaoni, 1965). In 
1964, Raphael Mechoulam was the first to report on chemical compounds extracted and isolated 
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from cannabis sativa which contributed to the biological activity of the plant. While discovering 
several active compounds of similar lipid structural class, he isolated Δ9-tetrahydrocannabinol 
(THC) as the primary psychoactive compound responsible for marijuana’s activity (Gaoni and 
Mechoulam, 1964). The FDA has since approved Marinol
®
 (synthetic THC) for the treatment of 
AIDS related anorexia and emesis induced by chemotherapy. In Canada and Europe, Sativex
®
 
(THC:cannabidiol; 1:1) is approved for the management of cancer pain and neuropathic pain 
associated with multiple sclerosis. However, marijuana and THC have several non-approved 
beneficial applications such as anxiolysis, management of chronic pain and treatment of abuse 
disorders. However, dependence, particularly withdrawal from prolonged cannabinoid use, 
which limits clinical utility of cannabis and its psychoactive ingredients as well as direct acting 
CB1 receptor agonists. 
Cannabinoid dependence 
Studies of cannabis dependence and withdrawal in humans 
While classical cannabinoids such as THC have many promising clinical applications, 
including the treatment of opiate dependence, the therapeutic potential of marijuana as well as 
THC is limited by their dependence liability. While the current revisions of the DSM-IV and 
ICD-10, the two most common diagnostic guidebooks used by medical professionals today to 
diagnose substance-use disorders, include criteria and symptomology for diagnosing cannabis 
abuse and dependence, only the latter recognizes a withdrawal syndrome as a component of a 
cannabis dependence disorder (American Psychiatric and American Psychiatric Association. 
Task Force on, 2000). The DSM-IV reflects a common attitude of many in medicine and the 
general public that cannabis is not a physically addictive substance in which a withdrawal 
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syndrome can produce clinically relevant symptoms of any severity and duration to impact 
subsequent substance-use behavior. The source of this belief is likely due to a multitude of 
factors, such as the relatively slow onset and unique constellation of the withdrawal syndrome, 
and is further described below.  
Cannabis is the most commonly used illicit drug worldwide, with approximately 56% of 
young adults (i.e., 19-28 years) in America having tried cannabis in their lifetime (Johnston, 
2010) . This high prevalence of marijuana use allows for many people to have personal and/or 
anecdotal experience with marijuana without necessarily having personal interactions with 
dependent users. So while only about 3-4% of individuals who have ever tried cannabis meet 
criteria for a cannabis-use disorder (compared with 15-25% for cocaine), the total number of 
Americans classified with such disorders is 4.3 million, more than twice that of cocaine and 
heroin combined (SAMHSA and Studies, 2008). In addition, the severity of cannabis 
withdrawal is not generally associated with any symptoms requiring hospitalization or viewed 
as potentially life-threatening (Wallace and Cunningham, 1944). Furthermore, only a subset of 
regular marijuana users experience a clustering of symptoms upon cessation of use, with reports 
of frequency ranging from 1/6 up to 1/2 (Wiesbeck et al., 1996; Budney et al., 1999). Common 
symptoms observed during cannabis withdrawal include anger, aggression, irritability, 
anxiety/nervousness, decreased appetite or weight loss, restlessness, and sleep difficulties with 
strange dreams (Budney and Hughes, 2006). Marijuana withdrawal has been compared to that 
of tobacco, and is reported to increase craving and desire to resume use (Budney et al., 2008; 
Vandrey et al., 2008). A similar abstinence syndrome has also been shown upon cessation of 
repeated oral THC, the primary psychoactive component of marijuana, in human studies (Haney 
et al., 1999). While the immediate physical impact of these symptoms are mild when compared 
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to certain other drugs of abuse the comprehensive impact of the cannabis withdrawal syndrome 
is becoming better understood. However, any abstinence syndrome may increase the desire to 
continue drug use and thus, represents a complication in treating dependence from other drugs 
of abuse.[For a complete review see (Ramesh et al., 2011b)] 
Neurobiological adaptations during cannabinoid dependence 
In addition to the increased characterization of a behavioral profile during cannabinoid 
withdrawal, preclinical studies have investigated the molecular changes that result from 
repeated exposure, and cessation, of cannabinoids. Such studies provide indicators of 
adaptations that drive withdrawal symptomology, and improve strategic targeting of 
therapeutics. Chronic administration of cannabinoid agonists results in down-regulation of the 
CB1 receptor in several brain regions (e.g., cerebellum, hippocampus and striatum with globus 
pallidus) as measured by radioligand binding (Breivogel et al., 1999). At the level of the G-
protein, chronic treatment with THC produces a time and region-dependent desensitization of 
CB1 receptor activity (Romero et al., 1997; Breivogel et al., 1999). Other evidence of 
dysregulation within the endocannabinoid system includes region-specific alterations in 
endocannabinoid content following precipitated withdrawal in rats and mice in the cerebellum, 
cortex, limbic forebrain and brainstem (Gonzalez et al., 2004).  
Alterations in numerous other neurotransmitter systems are also associated with 
withdrawal from THC in rodents. Following chronic administration of THC, brain levels of 
serotonin are decreased, concurrent with increases in its primary metabolite (Taylor and 
Fennessy, 1978; Taylor and Fennessy, 1982).  The finding that various serotonin uptake 
inhibitors elicited writhing behavior, backward kicks, jumps, and wet shakes in rats treated 
repeatedly with THC, suggests serotonergic involvement in cannabinoid withdrawal-like 
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behavior (Verberne et al., 1980).  In addition, histamine levels in  the brain decrease both during 
initial exposure to THC, as well as during somatic withdrawal induced by a serotonin reuptake 
inhibitor clomipramine (Verberne et al., 1985).  Several studies have shown evidence of 
upregulation and release of the stress-related peptide corticotropin-releasing factor upon 
precipitated withdrawal, a phenomenon common during withdrawal to many drugs of abuse 
(Rodriguez de Fonseca et al., 1997; Gonzalez et al., 2004). 
At the intracellular level, the cAMP second messenger signaling system appears to 
modulate cannabinoid withdrawal. Rimonabant administered to THC-dependent mice resulted 
in significant increases in both basal and forskolin-stimulated adenylyl cyclase activity in the 
mouse cerebellum, but not in other regions (Hutcheson et al., 1998). Similar results were 
obtained with calcium-calmodulin stimulated cyclase activity from cerebella of THC-dependent 
rats undergoing precipitated withdrawal (Rubino et al., 2000). Rimonabant-precipitated 
cannabinoid withdrawal also results in upregulation of protein kinase A (PKA) activity, which 
is downstream of cAMP, in the cerebella of THC dependent rats (Tzavara et al., 2000). 
Additionally, infusions of the cAMP blocker Rp-8Br-cAMPs into the cerebellum attenuated 
expression of precipitated withdrawal signs and PKA activity in rats undergoing precipitated 
withdrawal. Conversely, infusion of Sp-8Br-cAMPs, a cAMP analog, into the cerebellum 
elicited cannabinoid withdrawal somatic signs in drug naïve mice. These findings provide 
strong evidence for the functional role of the cAMP cascade, particularly in the cerebellum, in 
modulating withdrawal from cannabinoids. 
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The endocannabinoid system 
Cannabinoid receptors 
THC, as well as many other cannabinoids, has been demonstrated to bind to and activate 
two types of cannabinoid receptors that have been cloned, CB1 (Matsuda et al., 1990) and CB2 
(Gerard et al., 1991). Both cannabinoid receptors are G-protein coupled receptors, which are 
associated with Gi/o G-proteins [for a complete review see (Howlett, 2002)]. Activation of these 
receptors decreases cAMP production via blockade of adenylyl cyclase (Howlett et al., 1990), 
activation of inwardly rectifying potassium (GIRK) channels via Gβγ subunits (Mackie et al., 
1995; McAllister et al., 1999). Furthermore activation of the cannabinoid receptors inhibits N- 
and P/Q-type calcium channels, which reduces synaptic vesicle fusion to the nerve terminal 
thereby inhibiting the release of excitatory and inhibitory neurotransmitters. The CB1 receptor is 
heterogeneously expressed throughout the central nervous system (CNS) and periphery 
(Herkenham et al., 1990; Matsuda et al., 1993; Felder and Glass, 1998) and has been 
demonstrated to be responsible for most of the pharmacological actions of THC, particularly 
within the CNS. In support of this notion, cannabinoids induce tetrad effects (decrease in 
locomotor activity, hypothermia, catalepsy, and analgesia) which are reversed by a CB1 
antagonist and do not occur in CB1 (-/-) mice (Rinaldi-Carmona et al., 1994; Compton et al., 
1996b). The CB2 receptor is tightly associated with immune cells (Klein et al., 2003) and was 
initially believed to be expressed solely in the periphery. However, more recently this receptor 
has been found to be expressed in microglial cells (Cabral and Marciano-Cabral, 2005) and in 
neurons (Van Sickle et al., 2005) within the brain. CB1 and CB2 receptors share approximately 
44% homology with each other (Munro et al., 1993). Cannabinoid receptors have been localized 
on presynaptic terminals of both GABAergic (Katona et al., 1999) and glutamatergic neurons 
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(Huang et al., 2001; Szabo and Schlicker, 2005). Transient suppression of the inhibitory 
transmission (i.e. GABA) is termed depolarization-induced suppression of inhibition (DSI). 
Conversely transient suppression of the stimulatory neurotransmitter (e.g. glutamate) is called 
depolarized-induced suppression of excitation (DSE). Both result in cannabinoid receptor 
mediated hyperpolarization of a repetitively depolarized neuron, which suppresses subsequent 
vesicular fusion and release of glutamate or GABA. 
Endogenous ligands and their regulatory pathways 
A major breakthrough in cannabinoid pharmacology came with the discovery of the 
endogenous cannabinoids (endocannabinoids), which activate and bind to cannabinoid receptors 
(Di Marzo and Fontana, 1995). These endocannabinoids are derived from phospholipid 
precursors in the postsynaptic neuron. Unlike classical neurotransmitters, endocannabinoids are 
not stored in vesicles, but are released on demand and travel in a retrograde manner from post-
synaptic terminals to act on pre-synaptic cannabinoid receptors (Ahn et al., 2008). The most 
noteworthy endocannabinoids discovered are N-arachidonylethanolamine (anandamide, AEA) 
(Devane et al., 1992) and 2-arachidonylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 
1995). Additionally, three other endocannabinoids have been discovered, which include 
nolandin ether (Hanus et al., 2001), virodhamine (Porter et al., 2002) and N-arachidonyl 
dopamine (Huang et al., 2002). Despite sharing common receptors and considerable structural 
similarity, AEA and 2-AG can be distinguished by multiple factors. First, these 
endocannabinoids activate cannabinoid receptors to different degrees in vitro, with anandamide 
acting as a partial agonist whereas 2-AG acts a full agonist at the CB1 receptor (Gonsiorek et al., 
2000). Mice repeatedly treated with FAAH inhibitors as well as FAAH(-/-) mice show normal 
CB1 function and display CB1 desensitization following treatment with exogenous AEA. On the 
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other hand, prolonged exposure to the MAGL inhibitor JZL184 as well as MAGL(-/-) results in 
significant downregulation and desensitization of CB1 receptors as well as physical cannabinoid 
withdrawal (Falenski et al., 2010; Schlosburg et al., 2010). Second, the endogenous quantities 
of anandamide and 2-AG differ dramatically, with the latter being found at more than 100-fold 
higher concentrations in the nervous system (Ahn et al., 2009; Long et al., 2009a). Third, while 
AEA and 2-AG both activate CB1 and CB2, AEA has been has also been shown to activate 
vannilloid (TRPV1) and PPARα receptors (Ross, 2003; Jhaveri et al., 2008). Finally, the 
available signaling pool for each lipid is regulated by distinct synthetic and catabolic enzymatic 
pathways [(Ahn et al., 2008) summarized in Fig 2]. 
AEA synthesis is regulated by multiple pathways, and was initially believed to be 
formed via cleavage of N-arachidonylphosphatidylethanolamine (NAPE) by NAPE-
phospholipase D. However, it has been shown that NAPE-PLD knock-out mice possess wild-
type levels of AEA (Leung et al., 2006) suggesting that the existence of other biosynthetic 
pathways. Other pathways of AEA synthesis include via phosphodiesterase (PDE), or synthesis 
via cleavage of phospholipase C (PLC) and a phosphatase (Liu et al., 2006). On the other hand, 
2-AG is synthesized by the cleavage of diacylglycerol (DAG) by DAG lipase-alpha (DAGLα) 
(Gao et al., 2010; Tanimura et al., 2010). This is evidenced by the observation that DAGLα (-/-) 
mice when compared to DAGLβ (-/-) mice exhibit a significantly decreased production of 2-AG 
levels. 
As with most signaling messengers, AEA and 2-AG are rapidly inactivated soon after 
they are released. AEA is taken back into the post-synaptic terminal and degraded by the 
enzyme fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996). FAAH is located within the 
post-synaptic terminal (Gulyas et al., 2004) and is responsible for the degradation of other fatty 
13 
 
acid amides (FAAs) such as oleamide, the sleep agent, palmitoylethanolamide (PEA), the anti-
inflammatory agent, and oleylethanolamide (OEA) the satiety lipid (Cravatt et al., 1995). 
Conversely, approximately 85% of 2-AG is degraded within the presynaptic terminal by the 
enzyme monoacylglycerol lipase (MAGL), while the remaining 2-AG is degraded by enzymes 
alpha/beta hydrolase 6 and 12 (ABHD) (Blankman et al., 2007). Although 2-AG is present at 
levels 170-1000 fold greater than AEA (Sugiura et al., 2002), both endocannabinoids produce 
some similar cannabinoid effects in vitro. Administration of THC or other synthetic 
cannabinoids do not elicit effects mimicking the physiological effects of endocannabinoids 
because the former causes a persistent inhibition of neurotransmitter release, while the latter 
elicits localized and transient effects (Vaughan and Christie, 2005).  
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Figure 2. The endocannabinoid system (CNS): receptors, ligands and their regulatory pathways 
[Adapted from (Ahn et al., 2008)] 
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Inhibitors of endocannabinoid catabolic enzymes: second generation inhibitors 
It is noteworthy that blockade of the enzymes fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL) or their genetic deletion elevates brain levels of the 
respective endocannabinoids, AEA (Kathuria et al., 2003; Lichtman et al., 2004) and 2-AG 
(Long et al., 2009a).  FAAH (-/-) mice have been generated by inducing a targeted disruption of 
the FAAH gene by removing the first exon of the gene by homologous recombination. These 
mice show 10-fold elevations of AEA, other FAAs (e.g., OEA, PEA) in CNS and display an 
antinociceptive phenotype (Cravatt et al., 2001).  Irreversible (PF-3845, URB597) as well as 
reversible inhibitors of FAAH elevate AEA levels multi-fold in the brain (Fegley et al., 2005; 
Ahn et al., 2009). Importantly, PF-3845 is highly selective for FAAH, unlike URB597 that also 
binds to other serine hydrolases. Acute treatment with PF-3845 results in FAAH inhibition up to 
24 h and maximal AEA elevation up to 12 h in mice. In pharmacological assays, PF-3845 has 
analgesic effects in the lipopolysaccharide (LPS), chronic constrictive injury (CCI) and acetic 
acid stretching models of pain as well as anxiolytic-like effects in marble-burying assay (Kinsey 
et al., 2010; Booker et al., 2011; Kinsey et al., 2011b). 
Similarly MAGL, the primary degradative enzyme for 2-AG, represents a target for the 
development of selective inhibitors to treat pain and inflammatory, anxiety-related, and 
cannabis-related and other abuse disorders. Genetic deletion or complete pharmacological 
inhibition of MAGL with JZL184 increases brain 2-AG levels by approximately 10-fold (Long 
et al., 2009a; Long et al., 2009b; Schlosburg et al., 2010).  The pharmacological actions of 
JZL184 have been summarized in Table 1. It should be noted that JZL184 can also inhibit 
FAAH, though in vitro the compound is approximately 500-fold more selective as a MAGL 
inhibitor (IC50 = 8 nM) than as a FAAH inhibitor (IC50 = 4,000 nM) (Long et al., 2009a).  
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Although acute administration of 40 mg/kg JZL184 in ethanol:emulphor:saline (1:1:18) vehicle 
inhibits FAAH activity by approximately 50%, this inhibition is insufficient to increase brain 
AEA levels (Long et al., 2009b).   
Table 1. Pharmacological effects of JZL184 in preclinical assays 
Species Type of Assay Dosing Regimen Effect Reference 
Mouse Tetrad 
JZL184 (40 mg/kg, 
acute ;i.p.) 
Hypothermia, 
hypomotility, 
catalepsy, hyper-
reflexia 
(Long et al., 
2009a; Long et 
al., 2009b) 
Mouse Acetic acid stretching 
JZL184 (8, 16 
mg/kg; acute & 8 
mg/kg repeated; 
i.p.) 
Antinociception 
(Long et al., 
2009a; Busquets-
Garcia et al., 
2011) 
Mouse 
CCI (mechanical & 
cold allodynia) 
JZL184 (16,40 
mg/kg; acute; i.p.) 
Anti-allodynic 
(Kinsey et al., 
2009; Kinsey et 
al., 2010) 
Mouse; 
Rat 
Carrageenan-induced 
paw inflammation 
JZL184 (4-40 
mg/kg; i.p.) 
Partial anti-
allodynic and anti-
edema 
(Ghosh et al., 
2012; 
unpublished)  
Mouse Bone cancer pain 
JZL184 (10 μg; 
i.p.l) 
Anti-hyperalgesic 
(Khasabova et 
al., 2011) 
Mouse;
Rat 
Formalin pain test 
JZL184(16 mg/kg 
i.p.); (0.001-300 
µg; i.pl) 
Antinociceptive at 
both early and late 
phase 
(Long et al., 
2009a; Guindon 
et al., 2011) 
Rat Capsaicin-induced JZL184 (100µg; Antinociception (Spradley et al., 
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behavioral 
sensitization 
i.pl) and anti-
hyperalgesia 
2010) 
Mouse Marble burying 
JZL184 (16, 40 
mg/kg; i.p.) 
Anxiolysis 
(Kinsey et al., 
2011b) 
Mouse 
Elevated plus-maze; 
zero maze 
JZL184 (8 mg/kg; 
acute & repeated; 
i.p.) 
Anxiolysis:  
(Busquets-Garcia 
et al., 2011) 
Rat Elevated plus-maze 
JZL184 (4- 8 
mg/kg; acute & 
repeated; i.p.) 
Anxiolysis under 
high-stress 
(Sciolino et al., 
2011) 
Mouse 
NSAID induced 
gastric ulcers 
JZL184 (4 mg/kg; 
acute & repeated; 
i.p.) 
Prevents gastric 
hemorrhage 
(Kinsey et al., 
2011a) 
Mouse 
(TNBS)-induced 
colitis 
JZL184 (16 mg/kg; 
i.p.) 
Restoration of 
intestinal barrier 
integrity; 
inhibition of pro-
inflammatory 
cytokine release 
(Alhouayek et 
al., 2011) 
Shrew 
LiCl- induced 
vomiting 
JZL184 (16,40 
mg/kg; i.p.) 
Anti-emetic 
(Sticht et al., 
2011) 
Mouse 
THC physical 
withdrawal 
JZL184 (16 mg/kg; 
i.p.) 
Attenuation of paw 
flutters 
(Schlosburg et 
al., 2009) 
Mouse  Opioid withdrawal 
JZL184 (4-16 
mg/kg; i.p.) 
Attenuation of 
somatic 
withdrawal signs 
(Ramesh et al., 
2011a) 
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Mouse; 
rat 
DSE from Purkinje 
neurons in cerebellar 
slices and  DSI from 
CA1 pyramidal 
neurons in 
hippocampal slices 
JZL184 (1µM) 
Prolongation of 
DSE and DSI 
(Pan et al., 2009; 
Schlosburg et al., 
2010) 
Rat  
Aβ induced 
cytotoxicity and IHC 
in hippocampal 
neurons 
JZL184 (3µM) 
reduces Aβ-
induced 
neurodegeneration 
and apoptosis 
(Chen et al., 
2011) 
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Rationale and hypothesis  
Overall hypothesis 
Inhibition of the endocannabinoid catabolic enzymes FAAH and MAGL will reduce morphine 
withdrawal somatic signs and diarrhea in mice through the activation of cannabinoid receptors 
by anandamide and 2-AG, respectively. 
Selection of MAGL and FAAH inhibitors 
We specifically chose the respective irreversible MAGL and FAAH inhibitors, JZL184 and PF-
3845, since they are amongst the most selective inhibitors presently available (Ahn et al., 2009; 
Long et al., 2009b). The inhibitors are highly selective for either enzyme, have a long half-life 
(up to 24 h), produce profound (10-fold) elevations of the appropriate endocannabinoid (up to 
12 h) and have few off-site targets. It should be noted that JZL184 can also inhibit FAAH, 
although in vitro the compound is approximately 500-fold more selective as a MAGL inhibitor 
(IC50 = 8 nM) than as a FAAH inhibitor (IC50 = 4,000 nM) (Long et al., 2009a). In vivo, acute 
treatment with JZL184 leads to partial FAAH inhibition without elevation of AEA. However, 
repeated treatment with JZL184 leads to augmented levels of AEA in mice (Schlosburg et al., 
2010). 
Chapter 2. Dependence liability of MAGL and FAAH inhibitors 
In initial studies, we examined the dependence liability of FAAH and MAGL inhibitors 
in the precipitated cannabinoid withdrawal model. We employed FAAH (-/-) mice, FAAH 
inhibitors, and MAGL inhibitors to examine the role of endocannabinoid elevations in 
modulating established CB1-mediated responses (see Chapter 2). We expected that mice that 
had been subjected to prolonged FAAH inhibition would show no signs of precipitated physical 
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withdrawal. This prediction is based on previous studies demonstrating minimal drug abuse 
potential and adaptations of cannabinoid receptors following prolonged FAAH inhibition 
(Schlosburg et al., 2009; Falenski et al., 2010; Schlosburg et al., 2010). MAGL inhibition may 
have a greater potential of physical dependence than FAAH, as 2-AG is a full agonist and its 
concentration in brain is approximately 200 fold greater than that of anandamide. Simultaneous 
prolonged inhibition of both MAGL and FAAH is expected to lead to cannabinoid dependence, 
as dual inhibition acutely has shown numerous characteristics similar to THC not seen under 
conditions with either enzyme inhibited alone, notably catalepsy and THC substitution in 
discriminative stimulus testing. Finally, we evaluated the abuse liability of partial MAGL 
inhibition by using a low dose of JZL184 alone in combination with high dose of the FAAH 
inhibitor PF-3845. We predicted that development of cannabinoid dependence from prolonged 
MAGL inhibition is dose-dependent with rimonabant precipitating physical withdrawal in mice 
treated repeatedly with high doses of JZL184. 
Chapter 3. Effects of inhibitors on naloxone-precipitated opioid withdrawal – Somatic signs 
In Chapter 3, we described experiments that evaluated whether elevating 
endocannabinoids, through the inhibition of their catabolic enzymes, attenuates naloxone-
precipitated withdrawal symptoms in morphine-dependent mice. A growing body of literature 
demonstrates that elevating endogenous cannabinoids by inhibiting their hydrolytic enzymes 
offers potential therapeutic benefits, without the undesirable cannabimimetic actions of the 
exogenous cannabinoids. We investigated the efficacy of these inhibitors to reduce naloxone-
precipitated jumps, paw flutters, diarrhea and weight loss in mice implanted with morphine 
pellets.  The effects of these enzyme inhibitors were compared to those of THC. Selective CB1 
and CB2 receptor antagonists were employed to assess cannabinoid receptor involvement of the 
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anti-withdrawal effects of JZL184 and PF-3845. In order to evaluate whether compensatory 
changes of endocannabinoids occur during the state of withdrawal, AEA and 2-AG levels were 
quantified in brain regions associated with opioid dependence (i.e., the locus coeruleus (LC), 
periaqueductal grey (PAG), and amygdala).  We hypothesize that MAGL and FAAH inhibitors 
as well as THC will attenuate signs of precipitated opioid withdrawal through the activation of 
CB1 receptors. We suggest this hypothesis based on observations that THC and other exogenous 
cannabinoid agonists such as AEA and 2-AG have been demonstrated to reduce signs of 
naloxone-precipitated withdrawal signs in rodents (Hine et al., 1975; Bhargava, 1976; Vela et 
al., 1995; Yamaguchi et al., 2001). 
Chapter 4. Effects of MAGL and FAAH inhibitors on spontaneous opioid withdrawal signs 
In Chapter 4, we used the spontaneous withdrawal model since it represents high face 
validity for withdrawal typically experienced by opioid-dependent individuals. Accordingly, we 
investigated the dose response relationship of the MAGL inhibitor JZL184 to reduce 
spontaneous withdrawal induced jumps, paw flutters, head shakes, diarrhea and weight loss in 
mice implanted with morphine pellets.  Next, we tested the effectiveness of a novel combination 
of low-dose JZL184 and high dose of the FAAH inhibitor PF-3845 in reducing abrupt morphine 
withdrawal signs. This combination was selected in an attempt to produce maximal morphine 
anti-withdrawal effects, while minimizing side effects of JZL184 (see Chapter 4). The selective 
CB1 receptor antagonist, rimonabant was employed to assess cannabinoid receptor involvement 
of the anti-withdrawal effects of JZL184 and the combination. In order to evaluate whether 
compensatory changes of endocannabinoid system occurs following treatment with MAGL and 
FAAH inhibitors in ICR mice, endocannabinoid and arachidonic acid (AA) levels were 
quantified in whole brain. In addition, we measured changes in CB1 receptor binding and G-
22 
 
protein activation from brains of mice repeatedly treated with MAGL and FAAH inhibitors.  
We hypothesize that the combination will also reduce all signs of spontaneous withdrawal 
without inducing cannabimimetic behavioral effects and receptor adaptations. We predict these 
results based on the observation that the combination produces augmented analgesic efficacy 
and lacks dependence potential (Kinsey, Wise et al., unpublished data; Chapter 2 results). 
Chapter 5. Anti-diarrheal mechanism of action of MAGL inhibition: In vitro naloxone-
precipitated withdrawal - ileum 
Given the differential effects of MAGL and FAAH inhibition on diarrhea during 
morphine withdrawal we investigated the effects of JZL184 and PF-3845 on naloxone-
precipitated contractions in vitro in the ileum (Chapter 5).  The ileum offers a useful in vitro 
model to investigate opioid withdrawal (Paton, 1957).  Endocannabinoid catabolic enzyme 
inhibitors were also assessed for their efficacy in reducing electric field stimulated (EFS) 
contractions in naïve untreated ilea. Since it is known that cannabinoids such as THC and WIN-
55212 reduce naloxone-precipitated contractions in morphine-treated ilea, we hypothesize that 
MAGL and FAAH inhibitors will reduce naloxone-precipitated neurogenic contractions in a 
CB1-dependent manner. The precursors for diarrhea include both hyper-contractility as well as 
increased secretion of fluids and electrolytes. Hence, we also evaluated whether PF-3845 and 
JZL184 inhibit naloxone-precipitated hypersecretion of electrolytes in morphine-treated ileum 
in the Ussing’s chamber. To study the involvement of CB1 receptors we investigated the effects 
of JZL184 in morphine-treated ilea from CB1(-/-) mice. We hypothesized that both MAGL and 
FAAH inhibition will reverse naloxone-precipitated hypersecretion via CB1 mechanism since its 
known that cannabinoid agonists have anti-secretory effects in small intestine. To verify that 
pharmacological actions of MAGL inhibition are mediated by increases of 2-AG and/or 
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concomitant decreases in arachidonic acid levels, we quantified whether PF-3845 and JZL184 
alter endocannabinoids, free arachidonic acid, and prostaglandins in ileum.  
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Chapter 2: Evaluation of rimonabant-precipitated withdrawal in mice subjected to 
prolonged inhibition of eCB catabolic enzymes 
In these experiments, we asked whether prolonged MAGL or FAAH blockade produces 
cannabinoid physical dependence, a phenotype that has been observed in rodents that have been 
exposed to repeated treatments with direct CB1 agonists.  
Preclinical Studies of Cannabinoid Dependence  
Repeated administration of THC or other cannabinoid agonists leads to dependence in a 
variety of laboratory animals. Preclinical models for assessing dependence include those for 
measuring reinforcing and rewarding properties, such as self-administration, conditioned place 
preference, and intracranial self-stimulation (for a complete review see Panagis et al., 2008) as 
well as withdrawal signs.  The withdrawal can include both physiological signs, as well as 
indicators of emotional state. 
a. Characterization of cannabinoid withdrawal 
The two general procedures used to induce a state of drug withdrawal in preclinical drug 
dependence studies are spontaneous withdrawal and precipitated withdrawal. Spontaneous 
withdrawal occurs following abrupt cessation of the drug, which is metabolized and cleared 
from the body. In precipitated withdrawal, an appropriate selective receptor antagonist is used 
to displace the agonist from the receptor resulting in the rapid onset of withdrawal symptoms. 
The specific withdrawal symptoms, intensity, and duration depend on the pharmacologic 
characteristics of the compound, with drugs from the same class generally sharing similar 
withdrawal syndromes. The precipitated withdrawal model is employed more often than the 
spontaneous withdrawal model to investigate cannabinoid dependence in laboratory animals 
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because of the long half-life of THC and subtle withdrawal effects make it difficult to observe 
and quantify upon abrupt cessation. The results of preclinical studies employing precipitated 
and spontaneous withdrawal procedures are shown in Table 2.  
b. Spontaneous Cannabinoid Withdrawal in Laboratory Animals 
The quantification of abrupt withdrawal signs in laboratory animals is very challenging as 
THC has a long half-life (Huestis, 2005) resulting in delayed onset and longer duration of 
withdrawal symptoms. The results from laboratory studies have often been mixed. The study of 
somatic withdrawal signs from repeated administration of THC and other cannabinoids has been 
examined in different animal species. While a variety of abnormal behavior signs, such as 
tremors, wet dog shakes and hyperirritability, have been reported in rats (Kaymakcalan et al., 
1977), other studies failed to find significant abrupt withdrawal signs in rodents (Leite and 
Carlini, 1974; Aceto et al., 1996). Similarly, spontaneous withdrawal signs were not observed in 
pigeons following chronic exposure to THC (McMillan et al., 1973). Rhesus monkeys 
chronically infused with intravenously administered THC (0.5 mg/kg q.i.d. for 3 weeks) 
displayed substantial increases in gross movement, eye contact, and  tooth baring during the 
first week of abstinence (Fredericks and Benowitz, 1980). These behaviors reflect rebound 
withdrawal symptoms, as they were initially suppressed by acute THC and subsequently 
underwent tolerance. In another study, food reinforced operant responding was decreased in 
monkeys following upon abrupt cessation of drug infusions (Beardsley et al., 1986). 
Spontaneous withdrawal responses also occur following discontinuation from chronic 
administration of the full cannabinoid receptor agonists WIN-55, 212 in rats (Aceto et al., 2001) 
and CP-55,940 in mice (Oliva et al., 2003). The data from these studies suggest that while 
spontaneous withdrawal from cannabinoids can be observed in experimental animals, the ability 
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to observe and quantify these withdrawal effects depends on various factors such as: the 
species, cannabinoid selected, duration of drug administration, the time point at which 
withdrawal is assessed, and the specific end points. While the spontaneous withdrawal 
procedure presents with considerable challenges and may be prone to false negatives because of 
the slow elimination of THC and its metabolites (Huestis, 2005), it is considered to possess 
more face validity than precipitated withdrawal procedure for modeling human cannabis 
withdrawal. 
c. Precipitated Cannabinoid Withdrawal in Laboratory Animals 
The development of the CB1 receptor antagonist rimonabant (Rinaldi-Carmona et al., 1994) 
and other CB1 receptor antagonists has provided highly useful tools to investigate precipitated 
withdrawal in cannabinoid-dependent animals. Rimonabant binds with high affinity to the CB1 
receptor and antagonizes the pharmacological effects of many cannabinoid receptor agonist 
activities in laboratory animals and humans (Rinaldi-Carmona et al., 1994; Compton et al., 
1996a; Lichtman et al., 1998b; Winsauer et al., 1999; Huestis et al., 2001; Huestis et al., 2007). 
Somatic Withdrawal Signs: Soon after the discovery of rimonabant, two separate groups 
independently used this antagonist to demonstrate somatic precipitated withdrawal signs in rats. 
These withdrawal signs include wet-dog shakes, forepaw fluttering, chewing, increased 
horizontal and vertical activity, retropulsion, and ptosis (Aceto et al., 1995; Tsou et al., 1995). 
Rimonabant also precipitates a profound withdrawal syndrome in mice that are chronically 
exposed to either THC or marijuana smoke (Cook et al., 1998; Wilson et al., 2006). The 
withdrawal signs commonly observed in mice, such as paw tremors and wet dog shakes, are 
observed consistently across all strains (Cook et al., 1998; Huang et al., 2009). Other signs such 
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as mastication, sniffing, and pilerection are of low frequency, but are scored in a cannabinoid 
composite withdrawal index (Hutcheson et al., 1998; Ledent et al., 1999; Tzavara et al., 2000; 
Lichtman et al., 2001b). It should be noted that rimonabant can also produce pharmacological 
effects in naïve animals that resemble withdrawal symptoms [for a review see(Lichtman and 
Martin, 2005)], including increases in ear scratching, head-shakes, and increased grooming 
behavior (Cook et al., 1998; Darmani and Pandya, 2000).  Thus, it is critical to include 
appropriate vehicle-treated control groups in studies employing a CB1 receptor antagonist to 
precipitate cannabinoid withdrawal to control for intrinsic effects of the drug at testing.  
Nonetheless, the observation that rimonabant elicits a far greater magnitude of withdrawal-like 
behavior (e.g., head shakes and paw tremors) in subjects receiving repeated administration of 
THC or repeated exposure to marijuana smoke than control animals (Cook et al., 1998; Wilson 
et al., 2006) supports the utility of this precipitated withdrawal model.  
Aversive and Subjective Signs: There are few reports examining aversive or emotional 
responses in rodents undergoing cannabinoid withdrawal. Rimonabant challenge to THC-
dependent mice elicited decreased time in open arm time in the elevated plus maze test (Huang 
et al., 2010), suggesting the occurrence of an anxiogenic-like state in subjects undergoing 
cannabinoid withdrawal, but failed to elicit aversive/dysphoric effects in the conditioned place 
aversion test (Hutcheson et al., 1998). In THC-dependent dogs, rimonabant precipitates a 
withdrawal syndrome that includes distinct gastrointestinal signs such as diarrhea, vomiting, 
excessive salivation as well as decreases in social behavior and increases in restless behavior 
and trembling (Lichtman et al., 1998a). Other studies are focusing on subjective signs of 
cannabinoid withdrawal. Monkeys chronically treated with THC demonstrated robust 
discrimination of the CB1 antagonist rimonabant (McMahon and France, 2003; McMahon, 
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2006; Stewart and McMahon, 2010). THC discontinuation produced a similar discriminative 
stimulus to rimonabant in THC-treated animals. The data suggest that the interoceptive cues of 
THC cessation-induced abstinence are mediated by the CB1 receptor.  
Precipitated Withdrawal with Other Cannabinoid Agonists: Rimonabant also precipitates 
withdrawal signs following chronic administration of other cannabinoid agonists such as 
anandamide, methanandamide, WIN-55,212, CP-55,940 and HU-210 (Rodriguez de Fonseca et 
al., 1997; Aceto et al., 1998; Rubino et al., 1998; Aceto et al., 2001). The withdrawal syndrome 
precipitated following repeated anandamide administration is not as robust as with other 
cannabinoids (Costa et al., 2000; Falenski et al., 2010).  
Table 2. Preclinical studies investigating cannabinoid withdrawal employing precipitated and 
spontaneous withdrawal procedures  
Species Type of 
Withdrawal 
Agonist, Dosing Regimen, 
Route of Administration 
Dependent 
Variable 
Reference 
Mouse Precipitated THC, 6.5 days: 10 mg/kg 
s.c. (b.i.d.)  
Somatic signs (Cook et al., 
1998) 
Mouse Precipitated THC, 5.5 days: 10 20 
mg/kg i.p. (b.i.d.)  
Somatic signs, 
adenylyl cyclase 
overshoot in 
cerebellum 
(Hutcheson et 
al., 1998) 
Mouse Precipitated THC, 5.5 days: 20 mg/kg 
i.p. (b.i.d.)  
Somatic signs (Valverde et al., 
2000) 
Mouse Precipitated THC, 6.5 days: 10 mg/kg Somatic signs (Lichtman et al., 
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s.c. (b.i.d.)  2001a) 
Mouse Precipitated THC, 5.5 days: 20 mg/kg 
i.p. (b.i.d.)  
Somatic signs, body 
wt.  
(Anggadiredja et 
al., 2003) 
Mouse Spontaneous CP, 6.5 days: 0.5 mg/kg i.p. 
(b.i.d.) 
Increased locomotor 
activity, endocrine 
gene transcription 
levels 
(Oliva et al., 
2003) 
Mouse Precipitated THC, MAR, 5 days: 200 
mg; 5 or 10 mg/kg/ i.v. 
(s.i.d.) 
Somatic signs (Wilson et al., 
2006) 
Mouse Precipitated THC, 5.5 days: 20 mg/kg 
i.p. (b.i.d.)  
Somatic signs (Tourino et al., 
2007) 
Mouse Precipitated THC, 4.5 days: 25 mg/kg 
s.c. (b.i.d.)  
Somatic signs, 
activity 
(Huang et al., 
2009) 
Mouse Precipitated THC, 5.5 days: 50 mg/kg 
s.c. (b.i.d.); 10 mg/kg 
(s.i.d.) 
Somatic signs (Schlosburg et 
al., 2009) 
Mouse Precipitated THC, AEA, 5.5 days: 50 
mg/kg s.c. (b.i.d.)  
Somatic signs (Falenski et al., 
2010) 
Mouse Precipitated THC, 10 days: 10 mg/kg 
s.c. (s.i.d.) 
Anxiogenic-like 
effects (plus maze)  
(Huang et al., 
2010) 
Mouse Precipitated JZL184 (40 mg/kg), THC 
(10,50 mg/kg) 6 days  
Somatic signs (Schlosburg et 
al., 2010) 
30 
 
Rat Precipitated THC, 4 days: 0.5-4; 2.5-20; 
12.5-100 mg/kg/hr. i.p. 
Somatic signs (Aceto et al., 
1995) 
Rat Precipitated THC, 6.5 days: 15 mg/kg 
i.p. (b.i.d.)  
Activity (Tsou et al., 
1995) 
Rat Precipitated, 
spontaneous 
`THC, 4 days: 12.5-100; 
2.5-20; 0.5-4 mg/kg/ 24hr. 
i.p. (cont.)  
Somatic signs with 
precipitated only 
(Aceto et al., 
1996) 
Rat Precipitated THC, 6.5 days: 15 mg/kg 
i.p. (b.i.d.)  
Somatic signs (Diana et al., 
1998) 
Rat Precipitated CP, 6.5 days: 0.4 mg/kg i.p. 
(b.i.d.)  
Somatic signs, 
activity 
(Rubino et al., 
1998) 
Rat Precipitated THC, 6 days: 10-30; 10-40; 
10-50 mg/kg s.c. (b.i.d.)  
Operant rate (Beardsley and 
Martin, 2000) 
Rat Precipitated, 
spontaneous 
WIN, 4 days: 1-8; 2-16; 4-
16 mg/kg/24 hr. i.p. (cont.)  
Somatic signs, body 
weight loss 
(Aceto et al., 
2001) 
Rat Precipitated THC, 4 days: 12.5-100 
mg/kg/24 hr. i.p. (cont.)  
Somatic signs (Breivogel et al., 
2003) 
Rat Precipitated HU210, 5.5 days: 100 
µg/kg i.p. (b.i.d.)  
Somatic signs (Cui et al., 2001) 
Rat Precipitated THC, 8 days: 10 mg/kg i.p. 
(b.i.d.)  
Somatic signs, 
activity 
(Gonzalez et al., 
2004) 
Dog Precipitated THC, 10 days: 0.6-1 mg/kg Somatic signs (Lichtman et al., 
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i.v. (b.i.d.) 1998a) 
Monkey Spontaneous THC, 10 days 0.05 
mg/kg/hour i.v.  
Operant rate 
suppression 
(Beardsley et al., 
1986) 
Monkey Precipitated, 
spontaneous 
THC, Continuous (drug 
discrimination study): 1 
mg/kg (b.i.d.)  
Somatic signs, 
operant rate 
suppression 
 (Stewart and 
McMahon, 
2010) 
AEA, anandamide; b.i.d., twice a day; HU-210, a synthetic cannabinoid; i.p., intraperitoneally; 
i.v., intravenously; CP, CP 55940; MAR, marijuana; s.c., subcutaneously; s.i.d, once a day; 
cont., continuous infusion;THC, Δ9-tetrahydrocannabinol; WIN, WIN 55212-2; (Ramesh et al., 
2011b). 
If targeting endocannabinoid catabolic enzymes is indeed a viable approach to treat other 
abuse disorders, it is important to know whether these inhibitors would themselves have abuse 
or dependence liability. FAAH inhibitors have been extensively investigated in a variety of such 
paradigms. Importantly, mice with persistently elevated anandamide levels following inhibition 
of FAAH, with the inhibitor URB597 and mice lacking the FAAH enzyme, do not show any 
withdrawal symptoms following treatment with rimonabant (Schlosburg et al., 2009; Falenski et 
al., 2010). Additionally, it has been demonstrated that URB597 does not produce rewarding 
effects in the rat conditioned place preference paradigm, does not substitute for THC in the drug 
discrimination paradigm, and is not self-administered in nonhuman primates (Gobbi et al., 
2005; Justinova et al., 2008). There is also supporting biochemical evidence that chronic 
treatment with FAAH inhibitors does not lead to long-term neural adaptations. Once-daily 
dosing with URB597 for 5 weeks exerted anxiolytic effects without altering CB1 messenger 
RNA levels (Bortolato et al., 2007). Likewise, repeated dosing of PF-3845 did not lead to 
desensitization or downregulation of CB1 receptors and did not alter CB1 receptor-mediated 
synaptic plasticity of hippocampal neurons. In contrast, sustained inactivation of MAGL, by 
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repeated treatment with high doses of JZL184 results in loss of its analgesic efficacy and 
produces cross-tolerance to the effects of other CB1 agonists in mice. Prolonged MAGL 
blockade with JZL184 also results in desensitization and downregulation of CB1 receptors as 
well as impaired endocannabinoid dependent synaptic plasticity (Schlosburg et al., 2010). To 
support the preceding literature, we investigated the ability of prolonged MAGL and FAAH 
inhibition, using both pharmacologic and genetic approaches, to elicit rimonabant-precipitated 
cannabinoid withdrawal in C57 mice. 
Methods 
Subjects 
Male C57BL/6J mice (Jackson laboratories) as well as male FAAH (-/-) and (+/+) mice 
backcrossed onto a C57BL/6J background for at least 13 generations (Cravatt et al., 2001) 
served as subjects. The mice weighed between 26 and 30 g and were housed 6-8 per cage in a 
temperature controlled (20-22
o
C) environment, in an American Association for the 
Accreditation of Laboratory Animal Care-approved facility. The mice were kept on a 12 h light/ 
dark cycle, with all experiments being performed during the light cycle.  Food and water were 
available ad libitum.  The study was performed with the approval of the Institutional Animal 
Care and Use Committee at Virginia Commonwealth University in accordance with the Guide 
for the Care and Use of Laboratory Animals. 
Drugs 
THC and CB1 receptor antagonist rimonabant were obtained from the National Institute 
on Drug Abuse (Bethesda, MD).  URB597 was purchased from Cayman chemicals (Ann Arbor, 
MI).  JZL184 and PF-3845 were synthesized as described previously (Ahn et al., 2009; Long et 
al., 2009a). THC, PF-3845, JZL184, rimonabant, and URB597 were dissolved in ethanol, 
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followed by addition of Emulphor-620 (Rhone-Poulenc, Princeton, NJ), and diluted with 0.9% 
saline to form a vehicle mixture of ethanol:emulphor:saline in a ratio of 1:1:18. All injections 
were administered in volume of 0.01 ml per 1 g body weight.  THC was administered via 
subcutaneous (s.c.) injection, whereas PF-3845, JZL184, rimonabant, and URB597 were given 
via intraperitoneal (i.p.) injection.  PF-3845 and JZL184 were given 2 h before testing, to 
coincide with peak levels of AEA and 2-AG elevations, respectively, following systemic 
administration (Ahn et al., 2009; Long et al., 2009a). THC was given 30 min before rimonabant 
treatment.   
Rimonabant-precipitated cannabinoid withdrawal 
The mice were given a once daily injection of PF-3845 (10mg/kg, i.p.), JZL184 
(4/8/16/40mg/kg, i.p.) or Δ9–THC (10mg/kg s.c.) for 6 days. Under all conditions mice were 
give an i.p. injection of rimonabant 2 hr after the last injection of PF-3845, JZL184 and JZL195 
or 30 mins after last THC injection.  
Behavior was then observed and recorded for 1 hr, using the ANY-maze™ software 
after the rimonabant injection. The videos were then scored by time-sampling examining 
periods of 5 min intervals, and then moving 5 min ahead on the video starting at minute 5 post-
rimonabant injection (i.e. 5-10 min, 15-20 min, etc).  At the end of the hour video, each animal 
had a similar sampled 30 min period observed and scored from their recordings. While several 
behavioral endpoints were observed that have been previously described in the literature as 
common in mice going through cannabinoid withdrawal (i.e. ptosis, retropulsion, piloerection, 
etc.), behaviors scored and presented are the most common, quantifiable, and with the highest 
inter-rater reliability (Cook et al., 1998).  The primary behavior observed was front paw flutters 
that included a range of behavior from single-paw tremors to full fluttering/shaking of both 
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paws simultaneously.  These motions of the paws are not typical of normal behavior. Also 
recorded were head twitches, which generally manifest as rotational shakes of the head, similar 
to what is described as “wet dog shakes” in rat. 
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Results 
2.1. Rimonabant-precipitated withdrawal potential following repeated FAAH inhibition 
The aim of this experiment was to examine whether repeated administration of FAAH inhibitors 
produces cannabinoid physical dependence.  Mice were treated with URB597 (10 mg/kg) or 
vehicle twice daily for 5.5 days and were challenged with rimonabant 1 h after their final 
injection. Rimonabant produced no significant differences between mice that were given 
repeated injections of URB597 and vehicle on paw tremors [p = 0.44; Figure 3A] as well as 
head twitching [p = 0.68; Fig. 3B]. We also tested the longer-acting, more selective second 
generation FAAH inhibitor, PF-3845.  Once-daily treatment with PF3845 (10 mg/kg) elicited 
minimal signs following rimonabant precipitation, with no significant differences in the 
intensity of paw flutters [p = 0.30; Fig. 3C] and head twitches [p = 0.39; Fig. 3D] in comparison 
to vehicle treated mice. 
2.2. Rimonabant precipitates withdrawal in mice treated repeated with high dose, but not low 
dose, JZL184  
In order to examine withdrawal potential from sustained blockade of MAGL, we evaluated 
rimonabant-precipitated withdrawal signs in mice treated with either vehicle or JZL184 (4, 8, 16 
or 40 mg/kg, i.p./once a day/ 6 days). JZL184 treatment led to an overall significant increase in 
the intensity of paw flutters [F(4,42) = 7.551; p<0.001; Fig. 4A]. Post-hoc analysis with 
Dunnett’s test showed that repeated treatment with high doses of JZL184 (viz. 16 and 40 
mg/kg) resulted in significant increases in incidence of paw flutters, and that withdrawal is not 
observed following repeated treatment with low doses of JZL184 (4 and 8 mg/kg). In addition, 
JZL184 treatment had no effect on the intensity of head twitches at any of the doses tested (Fig. 
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4B). This pattern of findings suggests that sustained and complete blockade of MAGL is 
necessary to elicit cannabinoid physical withdrawal. 
2.3. Rimonabant precipitates withdrawal in mice with simultaneous complete MAGL and 
FAAH inhibition 
In order to examine additional withdrawal potential due to simultaneous elevations in 
AEA and 2-AG, we treated both FAAH (+/+) and (-/-) mice treated repeatedly with the MAGL 
inhibitor JZL184.  Upon precipitation with the CB1 antagonist rimonabant, fluttering and head 
twitching incidences were recorded as representative of cannabinoid withdrawal.  As shown in 
Figure 5A, paw tremors were increased in mice treated with repeated JZL184 (40 mg/kg).  
Accordingly, there was a significant treatment effect [F(1,69)=45.0, p<0.001] for JZL184, 
however there was no effect of genotype on the expression of paw flutters (p=0.29) nor an 
interaction between treatment and genotype (p=0.36).  When comparing to low-dose (10mg/kg 
daily) THC treated mice, JZL184 treated mice showed comparable elevations in fluttering 
versus vehicle treated mice (THC vs. JZL184 in FAAH (+/+): p=0.99; Scheffe’s post-hoc; Fig 
5A).  When examining head twitching response, shown in Figure 5B, there was an effect of 
treatment [F(4,77)=3.6, p<0.01].  Post-hoc analysis showed that the THC-treated mice were the 
only group to show elevated head twitching above that of vehicle treated groups (p<0.05; 
Scheffe’s post-hoc). 
To control for the possibility of developmental adaptations in FAAH (-/-) mice, follow- 
up experiments were performed using pharmacological means of dual MAGL-FAAH inhibition.  
This experiment tested combined administration of JZL184 (40 mg/kg) and PF3845 (10 mg/kg).  
Repeated treatment with PF-3845 did not lead to physical withdrawal signs following 
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rimonabant challenge. In addition, PF-3845 did not alter the magnitude of paw flutters 
following rimonabant challenge in mice given repeated JZL184 [F(3, 28) = 10.0, p < 0.001; 
Figure 6A].  While there was an overall treatment effect on head twitches [F(3, 28) = 3.5, p < 
0.05; Figure 6B], no individual group was significantly elevated from  vehicle.  
2.4. Sustained simultaneous partial MAGL and complete FAAH inhibition does not lead to 
physical withdrawal on rimonabant challenge 
Finally, we evaluated whether repeated treatment with a combination of low-dose JZL184 and 
high-dose PF-3845 would also lead to cannabinoid physical withdrawal. This combination was 
selected to retain beneficial therapeutic effects of MAGL and FAAH inhibition while avoiding 
side-effects of complete MAGL inhibition. In this experiment, mice were repeatedly treated 
with either vehicle, JZL184 (40mg/kg) or JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) for 6 days 
and followed by rimonabant challenge 2hr after the last injection. While rimonabant precipitated 
paw flutters in mice treated with the high dose JZL184, mice treated with the combination of 
low dose JZL184 and high dose PF-3845 did not exhibit elevated paw flutters [F(2,21) = 
14.101; p<0.001; Fig. 7A]. Neither treatment elicited significantly elevated head twitches in 
comparison to vehicle treated mice (Fig. 7B).  
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Figure 3. Evaluation of rimonabant-precipitated withdrawal signs following repeated high-
dosing of FAAH inhibitors.   
The first generation, short-acting inhibitor URB597 was given at 10 mg/kg twice daily, while 
the more potent and longer-acting inhibitor PF3845 was given daily at a dose of 10 mg/kg.  
Neither FAAH inhibitor given repeatedly elicited (A) and (C) paw flutters  or (B) and (D) head 
twitches compared to vehicle.  Data represented as mean ± SEM; n = 8 mice/ group.   
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Figure 4. Rimonabant-precipitated withdrawal in mice treated once a day for 6 days with the 
MAGL inhibitor JZL184 (4,8,16 or 40 mg/kg) or vehicle.  
(A) Rimonabant precipitated a significantly increased intensity of paw flutters in mice treated 
with 16 mg/kg and 40 mg/kg JZL184 in comparison to vehicle treated mice. In contrast, mice 
treated with 4 mg/kg and 8 mg/kg JZL184 did not exhibit elevated incidences of paw flutters. 
(B) Neither dose of JZL184 precipitated a siginificantly altered intensity of head twitches. Data 
represented mean ± SEM; n=7-11 mice/ group; *p< 0.05 v/s vehicle control.  
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Figure 5.  Prolonged elevation of 2-AG, by repeated  JZL184 administration, leads to signs of 
cannabinoid physical dependence in both FAAH (+/+) and (-/-) mice 
(A) Mice treated with 6-day JZL184 (40 mg/kg) show significant paw fluttering withdrawal 
behavior upon precipitation with the cannabinoid antagonist rimonabant (10 mg/kg) equally in 
both FAAH (+/+) and (-/-) mice.  The level of fluttering is comparable to that of a 6-day 
moderate dose of THC (10 mg/kg).  (B) JZL184 did not elicit head twitch behavior in a manner 
similar to THC treatment.  Data represented as mean ± SEM; n = 8-15 per group, ***p < 0.001 
v/s respective vehicle controls. 
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Figure 6. Cannabinoid precipitated withdrawal elicited by prolonged MAGL inhibition is not 
altered by simultaneous inhibition of FAAH.   
(A) Mice treated with 6-day JZL184 (40 mg/kg) show significant paw fluttering withdrawal 
behavior upon precipitation with the cannabinoid antagonist rimonabant (10 mg/kg), which is 
absent following 6-day FAAH inhibition via PF-3845 (10 mg/kg), nor enhanced by co-
administration of both enzyme inhibitors simultaneously.  (B) None of the combination of 
enzyme inhibitors elicited altered head twitching behavior.  n = 8 per group, ***p < 0.001 v/s 
respective vehicle controls. 
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Figure 7. Rimonabant does not precipitate withdrawal signs in mice treated repeatedly with a 
combination of low dose JZL184 and high dose FAAH inhibitor PF-3845   
(A) Rimonabant precipitated significantly elevated paw flutters in mice treated for 6 days with a 
high dose of JZL184 (40 mg/kg) but not in those treated with a combination of low-dose 
JZL184(4 mg/kg)  and PF-3845(10 mg/kg) (B) Head twitching behavior is not altered by either 
treatment. Data represented as mean ± SEM; n=8 mice/group; *p<0.05 v/s vehicle control. 
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2.5. Discussion  
 In these experiments we have examined the potential of repeated administration of 
MAGL and FAAH inhibitors to produce physical cannabinoid withdrawal in mice. Repeated 
treatment with the FAAH inhibitors, URB597 and PF-3845, did not lead to rimonabant-
precipitated cannabinoid withdrawal. On the contrary, prolonged treatment with high doses of 
the MAGL inhibitor JZL184 by itself or in combination with FAAH inhibition/deletion led to 
physical withdrawal on rimonabant challenge. However, repeated treatment with low doses of 
JZL184 or a combination of low dose JZL184 with PF-3845 did not lead to cannabinoid 
withdrawal. 
The ability of prolonged complete MAGL inhibition to elicit precipitated cannabinoid 
withdrawal represents a drawback of using these inhibitors in treatment of abuse disorders. It 
should be noted that the severity of withdrawal is comparable in magnitude to that of the lowest 
level of quantifiable withdrawal from repeated THC treatment. This may indicate that while the 
risk of physical dependence may exist, it is minimal compared to exogenous cannabinoid 
agonists. Also promising is the observation that though simultaneous complete FAAH and 
MAGL inhibition produces enhanced acute cannabinoid-mediated activity (Long et al., 2009c), 
there appears to be little enhanced magnitude of precipitated withdrawal compared to MAGL 
inhibition alone. This observation was replicated using both genetic and pharmacological tools. 
The lack of rimonabant-precipitated cannabinoid withdrawal signs by repeated URB597 
or PF3845 treatment adds to a growing body of literature demonstrating that FAAH inhibitors 
lack dependence potential (Solinas et al., 2007; Justinova et al., 2008) that are typical of 
exogenous cannabinoids. While prolonged treatment with high doses of JZL184 leads to 
cannabinoid dependence; repeated treatment with low, pharmacologically active doses of 
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JZL184 at 4 and 8 mg/kg did not lead to physical withdrawal. JZL184 at these doses also does 
not undergo tolerance to its analgesic effects in the CCI and carrageenan pain assays (Kinsey et 
al., Ghosh et al., unpublished data). Finally, rimonabant did not precipitate withdrawal in mice 
repeatedly treated with a combination of low-dose JZL184 (4 mg/kg) and PF-3845 (10 mg/kg). 
This combination produces augmented anti-allodynic effects in both the CCI and carrageenan 
pain assays and repeated treatment does not lead to tolerance or functional CB1 receptor 
adaptations in C57BL6/J mice (Wise et al, unpublished data). The lack of dependence and 
analgesic tolerance following repeated administration of FAAH inhibitors and low doses of 
JZL184 indicates that they are a viable target for the treatment of chronic pain conditions and 
abuse disorders. 
Thus, elevation of the two primary endocannabinoids in brain leads to different 
consequences on physical dependence. These differential actions of prolonged MAGL and 
FAAH inhibition are not fully understood and may be partly attributed to (1) higher 
concentrations of 2-AG compared with anandamide after sustained blockade of their 
degradative enzymes and (2) differences in the efficacy of these endocannabinoids at the CB1 
receptor (Howlett and Mukhopadhyay, 2000) or (3) the result of regionally or neuron selective 
production and release of eCBs.  
 
.  
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Chapter 3: Effects of inhibition of eCB catabolic enzymes on precipitated somatic opioid 
withdrawal signs 
A case report from the 19th century suggested that an extract of Cannabis sativa may 
ameliorate opiate addiction (Birch, 1889). In this report, a tincture of cannabis extract alleviated 
signs of opioid abstinence such as lack of appetite, anorexia, disordered bowels and conscious 
delusions in an opium poppy addict. Modern studies corroborated this idea by demonstrating 
that THC, the primary psychoactive constituent of cannabis, attenuates the intensity of 
naloxone-precipitated opioid withdrawal signs in morphine-dependent rodents (Hine et al., 
1975; Bhargava, 1976). A low oral dose of THC when co-administered with high-dose oral 
morphine attenuated the development of dependence and expression of withdrawal signs in 
mice (Cichewicz and Welch, 2003). A 30-day pretreatment with THC also resulted in decreased 
withdrawal signs in morphine-dependent mice (Jardinaud et al., 2006). The CB1 receptor 
appears to play a significant role in modulating dependence to morphine and other opiates. CB1 
(-/-) mice show significantly reduced self-administration of morphine and attenuated naloxone- 
precipitated morphine withdrawal signs (Ledent et al., 1999; Lichtman et al., 2001b).  Other 
exogenous cannabinoid agonists such as AEA and 2-AG have been demonstrated to reduce 
signs of naloxone-precipitated withdrawal signs in rodents (Vela et al., 1995; Yamaguchi et al., 
2001). A growing body of literature demonstrates that elevating endogenous cannabinoids by 
inhibiting their hydrolytic enzymes offers potential therapeutic benefits, without the undesirable 
cannabimimetic actions of the exogenous cannabinoids (Solinas et al., 2007; Ahn et al., 2008; 
Justinova et al., 2008; Ahn et al., 2009). It has been reported that there are significant changes in 
brain levels of endocannabinoids following chronic morphine treatment (Gonzalez et al., 2003; 
Vigano et al., 2004; Caille et al., 2007). These findings support the notion that 
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endocannabinoids and the CB1 receptor play an important role in modulating the expression of 
opioid withdrawal. In this section, we describe experiments that evaluated whether elevating 
endocannabinoids, through the inhibition of their catabolic enzymes, attenuates naloxone-
precipitated withdrawal symptoms in morphine dependent mice. The precipitated withdrawal 
model will enable a relatively high throughput initial screen of the inhibitors to assess their anti-
withdrawal effects. We investigated the efficacy of the respective MAGL and FAAH inhibitors, 
JZL184 and PF-3845, as well as THC to reduce naloxone-precipitated withdrawal signs. 
Additionally, we investigated whether the effects of these drugs in modulating opioid 
withdrawal are mediated through the CB1 receptor. 
Methods 
Subjects  
Selection of Strain: Initially C57BL6/J (25g; M/F) mice were used for studying withdrawal. 
However, morphine (75 mg) pellet implantation led to fatalities in approximately 40% of the 
mice, presumably due to respiratory depression or other consequences of overdose. Moreover, 
the surviving mice lost a significant portion of body weight during the 3 day period after pellet 
implantation. ICR mice (Harlan), on the other hand, did not exhibit significant fatalities and 
survived the 3 day pellet implantation without losing body weight. For the FAAH (-/-) studies, 
we found that using male mice weighing over 30 g increased survival rate to about 80% in this 
study. Given the increased mortality and morbidity observed following morphine pellet 
implantation in C57 mice, we selected ICR mice for the rest of the in vivo studies. 
Male ICR mice (Harlan laboratories; Indianapolis) as well as male FAAH (-/-) and (+/+) 
mice backcrossed onto a C57BL/6J background for at least 13 generations (Cravatt et al., 2001) 
served as subjects. The mice weighed between 26 and 30 g and were housed 6-8 per cage in a 
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temperature controlled (20-22
o
C) environment, in an American Association for the 
Accreditation of Laboratory Animal Care-approved facility. The mice were kept on a 12 h light/ 
dark cycle, with all experiments being performed during the light cycle.  Food and water were 
available ad libitum.  The study was performed with the approval of the Institutional Animal 
Care and Use Committee at Virginia Commonwealth University in accordance with the Guide 
for the Care and Use of Laboratory Animals. 
Drugs 
Morphine pellets (75 mg), placebo pellets, morphine sulfate, THC, the CB2 receptor 
antagonist SR144528, and the CB1 receptor antagonist rimonabant were obtained from the 
National Institute on Drug Abuse (Bethesda, MD).  Naloxone hydrochloride was purchased 
from Cayman chemicals (Ann Arbor, MI).  JZL184 and PF-3845 were synthesized as described 
previously (Ahn et al., 2009; Long et al., 2009a). THC, PF-3845, JZL184, rimonabant, and 
SR144528 were dissolved in ethanol, followed by addition of Emulphor-620 (Rhone-Poulenc, 
Princeton, NJ), and diluted with 0.9% saline to form a vehicle mixture of 
ethanol:emulphor:saline in a ratio of 1:1:18. Naloxone and morphine were dissolved in 0.9% 
saline.  All injections were administered in volume of 0.01 ml per 1 g body weight.  THC and 
naloxone were administered via subcutaneous (s.c.) injection, whereas PF-3845, JZL184, 
rimonabant, and SR144528 were given via intraperitoneal (i.p.) injection.  PF-3845 and JZL184 
were given 2 h before testing, to coincide with peak levels of AEA and 2-AG elevations, 
respectively, following systemic administration (Ahn et al., 2009; Long et al., 2009a).  
Rimonabant, SR144528, and Δ9-THC were given 30 min before naloxone treatment.   
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Morphine pellet implantation surgery  
In order to induce opioid dependence, mice were implanted with morphine pellets as 
previously described (Way et al., 1969).  After induction of anesthesia with 2.5% isoflurane, the 
fur was shaved, the skin was disinfected with a sterile betadine swab (Purdue products, 
Stamford, CT), and a 1 cm horizontal incision was made in the midscapular region, using sterile 
surgical scissors.  A 75 mg morphine sulfate pellet was inserted subcutaneously, and the 
incision was closed with a sterile staple.  The mice were allowed to recover in heated home 
cages for 2 h after surgery and then returned to the vivarium until testing. 
Naloxone-precipitated opioid withdrawal  
Somatic withdrawal signs were scored, as previously described (Schlosburg et al., 
2009).  In brief, mice were placed in white acrylic chambers (20x20 cm), with a clear acrylic 
front panel and a mirrored back panel for a 30 min acclimation period.  The chambers were 
enclosed in sound-attenuating cabinets that contained an indirect filtered LED light source and 
fans for air circulation and white noise.  The mice were briefly removed from the chambers for 
naloxone administration and immediately returned to the chambers for a 30 min observation 
period.  Behavior was recorded using a series of Fire-i
TM 
digital cameras (Unibrain, San Ramon, 
CA), and the videos were saved using the ANY-maze
TM
 video tracking software (Stoelting Co., 
Wood Dale, IL). Chambers were changed between tests and cleaned at the end of testing with 
an ammonia based cleanser and left to dry for two days, to allow for odors to dissipate.  The 
recorded videos were randomized and scored by a trained observer, who was blinded with 
respect to treatment condition. The primary behavioral signs of interest were frequency of 
jumps and front paw tremors (including single and double paw flutters and twitches, which are 
not commonly displayed by naïve mice). The occurrence of diarrhea during the testing period 
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was noted.  All behaviors were recorded as new incidences when separated by at least 1 s or 
interrupted by any other normal behavior. In addition, mice were weighed before and 
immediately after the 30 min test session to assess body weight loss.   
Extraction and quantification of brain and ileum endocannabinoid levels with LCMS  
Mice were implanted with placebo or morphine (75 mg) pellets, as described above.  On 
day 3, subjects received an s.c. injection of naloxone hydrochloride (1 mg/kg) or saline.  Ten 
min after naloxone injection, the mice were decapitated, and brains and segments of the ilea 
were harvested. Brains were removed and placed on a glass plate on ice for dissection.  A 
coronal section was taken using the median eminence on the ventral surface as a landmark.  
Specific areas of the brain relevant to opioid withdrawal were harvested, including the locus 
coeruleus (LC), periaqueductal gray (PAG), and the amygdala.  The anterior cut was made 
caudal to the optic chiasm and the posterior cut was made at the caudal extent of the 
hypothalamus, corresponding to approximately Bregma -0.6 to Bregma -2.6.  The amygdala 
was dissected using the optic tract medially and the external capsule dorsally as landmarks.  The 
sample included the amygdaloid nuclei and adjacent piriform cortex.  The brainstem was then 
placed with the dorsal surface exposed.  The PAG section was taken from the anterior superior 
colliculus to the caudal inferior colliculus, corresponding to approximately Bregma -3.3 to 
Bregma -5.3.  Cortex and hippocampus were discarded and the colliculi were removed.  Tissue 
ventral and lateral to the PAG was removed.  The sample included the PAG throughout its 
rostral-caudal extent, as well as adjacent reticulum.  The next consecutive section was taken by 
making a posterior cut at the anterior 1/4 of the cerebellum, corresponding to approximately 
Bregma -5.3 to Bregma -5.85.  The LC was dissected by removing the cerebellum and the 
ventral pons, then isolating the tissue lateral to the fourth ventricle.  The sample included the 
50 
 
locus coeruleus and adjacent parabrachial and tegmental nuclei. The brain areas and ileum 
segments were snap frozen in liquid nitrogen and stored at -80°C until lipid extraction. 
On the day of processing, tissues were weighed and homogenized with 1.4 ml 
chloroform/methanol (2:1 v/v containing 0.0348 mg PMFS/ml) after the addition of internal 
standards to each sample (2 pmol AEA-d8 and 1 nmol 2-AG-d8). Homogenates were then 
mixed with 0.3 ml of 0.73% w/v NaCl, vortexed, and then centrifuged for 10 min at 4,000 rpm 
(4° C). The aqueous phase plus debris were collected and extracted two more times with 0.8 ml 
chloroform. The organic phases from the three extractions were pooled and the organic solvents 
were evaporated under nitrogen gas. Dried samples were reconstituted with 0.1 ml chloroform 
and mixed with 1 ml ice-cold acetone. The mixtures were then centrifuged for 5 min at 3,000 
rpm and 4° C to precipitate the proteins. The upper layer of each sample was collected and 
evaporated under nitrogen. Dried samples were reconstituted with 0.1 ml methanol and placed 
in autosample vials for analysis.  
LC/MS/MS was used to quantify AEA and 2-AG. The mobile phase consisted of (10:90) 
water/methanol with 0.1% ammonium acetate and 0.1% formic acid. The column used was a 
Discovery HS C18, 4.6×15 cm, 3 μm (Supelco, PA). The mass spectrometer was run in 
Electrospray Ionization, in positive mode. Ions were analyzed in multiple-reaction monitoring 
mode, and the following transitions were monitored: (348>62) and (348>91) for AEA; 
(356>62) for AEAd8; (379>287) and (279>269) for 2-AG; and (387>96) for 2-AG-d8. A 
calibration curve was constructed for each assay based on linear regression using the peak area 
ratios of the calibrators. The extracted standard curves ranged from 0.03 to 40 pmol for AEA 
and from 0.05 to 64 nmol for 2-AG. 
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Statistical analysis  
All data are reported as mean ± SEM. In the behavioral experiments, non-continuous behaviors, 
including jumps and paw tremors, are presented as counted observations.  The occurrence of 
diarrhea was scored as a binary event for the entire 30 min period. Additionally, the mice were 
weighed before and after the testing period to determine total body weight loss (g). AEA, and 2-
AG levels are reported as pmol or nmol per gram of tissue, where applicable. Data were 
analyzed using t-test or two-way between measures analysis of variance (ANOVA), followed 
by Dunnett’s or Scheffe’s post hoc test. Differences of p<0.05 were considered significant. 
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Results 
3.1. Naloxone precipitates a profound withdrawal syndrome in morphine-dependent mice 
In order to establish the precipitated withdrawal model in our laboratory setting, mice 
were implanted with placebo or 75 mg morphine pellets and 72 h later, were challenged with an 
s.c. injection of naloxone. As shown in Fig. 8, naloxone precipitated somatic and autonomic 
withdrawal signs, including paw tremors (p<0.01), jumping behavior (p<0.01), diarrhea, and a 
significant loss in body weight (p<0.01). 
3.2. The MAGL inhibitor JZL184 and THC dose-dependently attenuate naloxone-
precipitated withdrawal signs in morphine-dependent mice through the activation of CB1 
receptors 
In the first set of experiments, we replicated previous work showing that THC attenuated 
naloxone-precipitated withdrawal in morphine-dependent mice (Bhargava, 1976). Seventy-two 
hours after morphine pellet implantation, mice were treated with vehicle or THC (1, 3, and 10 
mg/kg s.c.) and then administered naloxone 30 min later. THC dose-dependently reduced 
naloxone-precipitated jumping [F(4,30) = 4.7; p < 0.01; Fig. 9A] and paw fluttering [F(4,30) = 
11.3; p < 0.001; Fig 9B], weight loss [F(4,30) = 17.9; p < 0.001; Fig. 8C], and diarrhea (Fig 
9D), with the highest dose (10 mg/kg) completely abolishing diarrhea in all mice.   
In order to examine the role of MAGL inhibition in opioid withdrawal, we treated 
morphine-pelleted mice with either vehicle or JZL184 (4, 16, and 40 mg/kg, i.p.).  JZL184 
dose-dependently reduced naloxone-precipitated jumping [F(3,26) = 18.8; p < 0.001; Fig. 9A], 
paw fluttering [F(3,26) = 4.9; p < 0.01; Fig.9B], diarrhea (Fig. 9D), and weight loss [F(3, 26) = 
6.37; p < 0.01; Fig. 9C].  The highest dose of JZL184 (40 mg/kg) completely prevented the 
occurrence of diarrhea (Fig. 9D). 
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We next examined whether CB1 or CB2 receptors contribute to the protective effects of 
THC and JZL184 in the naloxone-precipitated withdrawal paradigm. The CB1 receptor 
antagonist rimonabant (3 mg/kg, i.p.) blocked the protective effects of THC on naloxone-
precipitated jumps (p < 0.05), paw flutters (p < 0.05), weight loss (p < 0.01), and diarrhea (Fig. 
8).  Rimonabant pretreatment also reversed JZL184-induced attenuation of withdrawal intensity, 
as indicated by significant interactions between JZL184 and rimonabant on jumps [F(1, 23) = 
8.6; p < 0.01; Fig. 10A], paw flutters [F(1, 23) = 8.2; p < 0.01; Fig. 10B] and weight loss [F(1, 
23) = 10.5; p < 0.01; Fig. 10C].  Similarly, the anti-diarrheal effects of JZL184 were completely 
reversed by rimonabant treatment (Fig. 10D). In contrast, treatment with the CB2 receptor 
antagonist SR144528 (3 mg/kg, i.p.) did not affect either the intensity of naloxone-precipitated 
withdrawal signs or JZL184-induced blockade of these withdrawal signs (Fig. 11).  The 
interaction between JZL184 pretreatment and SR144528 failed to achieve statistical 
significance for jumps [p = 0.24; Fig. 11A], paw flutters [p = 0.76; Fig. 11B] and weight loss [p 
=0.55; Fig. 11C].  In addition, SR144528 did not block the anti-diarrheal effects of JZL184 
[Fig. 11D]. Taken together, these data indicate that JZL184 attenuates naloxone-precipitated 
withdrawal symptoms through a mechanism that requires the activation of CB1 receptor. 
3.3. JZL184 maintains its anti-withdrawal effects after repeated treatment. 
In order to determine whether prolonged MAGL inhibition maintains anti-opioid 
withdrawal efficacy, we treated the mice for six days with the MAGL inhibitor JZL184 (4 or 40 
mg/kg, i.p.) during which time a 75mg morphine pellet was implanted on day 3.  Withdrawal 
was precipitated with an acute treatment of naloxone (1 mg/kg, s.c.) 72 h after pellet 
implantation. JZL184 (40mg/kg) reduced naloxone-precipitated jumping [F(2,20) = 5.422; p < 
0.01; Fig. 12A] but  did not significantly reduce the number of paw flutters (Fig. 12B) (p=0.58).  
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There was however, a significant reduction in the amount of weight loss [F(2,20) = 6.871; p < 
0.001; Fig. 12C] and percent of mice with diarrhea (Fig. 12D).  In contrast, repeated treatment 
with JZL184 (4mg/kg) did not affect any of the measured withdrawal symptoms. 
3.4. FAAH blockade attenuates somatic signs of naloxone-precipitated morphine withdrawal 
through a mechanism that requires the activation of CB1 receptors 
To elucidate the role of FAAH in morphine withdrawal, we first examined the impact of 
genetic deletion of FAAH on naloxone-precipitated morphine withdrawal.  FAAH (-/-) mice vs. 
FAAH (+/+) mice on a C57BL/6 background were implanted with 75 g morphine pellets and 
challenged with naloxone 72 h later.  FAAH (-/-) mice showed significant decreases in jumps 
(p<0.01; Fig. 13A), paw flutter incidents (p<0.05; Fig. 13B), and weight loss (p<0.05; Fig. 13C) 
compared with FAAH (+/+) mice.  Genetic deletion of FAAH did not affect the occurrence of 
naloxone-precipitated diarrhea [Fig. 13D].  These data support the idea that FAAH deletion 
attenuates the expression of some of the primary signs of naloxone-precipitated opioid 
withdrawal. 
We next evaluated the irreversible FAAH inhibitor, PF-3845 (10 mg/kg, i.p.) vs. vehicle 
on naloxone-precipitated morphine withdrawal.  PF-3845 significantly attenuated the frequency 
of jumps and paw flutters (Fig. 14A and B).  These effects were reversed by rimonabant as 
indicated by significant interactions between PF-3845 vs. vehicle and rimonabant vs. vehicle for 
jumps [F(1, 41) = 5.9; p <0.05; Fig. 14A] and paw flutters [F(1, 41) = 3.2; p < 0.01; Fig. 14B]. 
However, PF-3845 did not affect the weight loss during withdrawal (Fig. 14C), or the 
occurrence of diarrhea (Fig. 14D) following naloxone challenge.  This experiment shows that 
acute FAAH inhibition attenuates a subset of withdrawal signs (i.e., jumps and paw flutters) in a 
CB1 dependent manner, but does not reduce weight loss or diarrhea. 
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3.5. Measurement of endocannabinoid levels in brain following naloxone-precipitated 
withdrawal 
To determine if naloxone-precipitated withdrawal in morphine-dependent mice altered 
levels of endocannabinoids in brain regions associated with opioid dependence, we measured 
the levels of AEA and 2- AG in the LC, PAG, and amygdala.  Endocannabinoid levels were 
also measured in ileum. None of the treatments altered the levels of either endocannabinoid in 
any of the brain regions of interest or in the ileum (Table 1). 
Although it is well established that acute administration of JZL184 and PF-3845 
respectively increases 2-AG and AEA brain levels (Schlosburg et al., 2010), the effects of these 
inhibitors on endocannabinoid levels have not been measured in gastrointestinal tissue.  Thus, in 
the next experiment, we treated naïve mice with the enzyme inhibitors and quantified 
endocannabinoids in ileum.  As shown in Table 3, PF-3845 (10 mg/kg) significantly increased 
AEA, but not 2-AG, in the ileum.  In contrast, JZL184 did not significantly alter either 
endocannabinoid in ileum.    
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Figure 8. Naloxone precipitates somatic withdrawal signs in mice implanted with a 
subcutaneous morphine pellet (75 mg) for 3 days but not in mice implanted with a placebo 
pellet.  
The withdrawal signs measured included: (A) jumps, (B) paw flutters, (C) weight loss and (D) 
diarrhea. Data expressed as mean ± SEM. *p,0.05; **p < 0.01 v/s placebo control; n = 6-8 
mice/group 
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Figure 9. The primary psychoactive constituent of cannabis sativa THC and the irreversible 
MAGL inhibitor JZL184 attenuate the intensity of naloxone-precipitated withdrawal signs in a 
dose-dependent manner. 
 THC (30 min pretreatment) or JZL184 (2 h pretreatment) was given prior to naloxone (1 
mg/kg, s.c.). Rimonabant (3 mg/kg, i.p.) given 30 min before naloxone challenge antagonized 
the anti-withdrawal effects of THC (10 mg/kg, i.p.). The withdrawal signs measured included: 
(A) jumps, (B) paw flutters, (C) weight loss and (D) diarrhea. Data expressed as mean ± SEM 
for panels A-C. ***p<0.001, **p<0.01, *p<0.05 vs. vehicle; # p<0.05 vs. 10mg/kg THC; ## 
p<0.01 v/s THC(10mg/kg); n = 6-8 mice/group. 
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Figure 10. The MAGL inhibitor JZL184 attenuates the intensity of naloxone-precipitated 
morphine withdrawal signs in a CB1 receptor dependent manner 
 Rimonabant (3 mg/kg, i.p.) administered 90 min after JZL184 (40 mg/kg, i.p.) blocked the anti-
withdrawal effects of JZL184. The withdrawal signs measured were: (A) jumps, (B) paw 
flutters, (C) weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C. 
**p<0.01 vs. vehicle; ## p<0.01 vs. JZL184-vehicle; n = 6-8 mice/group. 
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Figure 11.  The reduction of intensity of naloxone-precipitated morphine withdrawal signs is not 
CB2 receptor mediated.  
The CB2 antagonist SR144528 (3 mg/kg, i.p.) did not reverse the anti-withdrawal effects of 
JZL184 (40 mg/kg, i.p.). The withdrawal signs measured were: (A) jumps, (B) paw flutters, (C) 
weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C. ***p<0.001, 
**p<0.01 vs. vehicle; n = 7-8 mice/group. 
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Figure 12: JZL184 maintains it anti-withdrawal effects following repeated treatment in 
morphine-dependent mice 
Repeated treatment with JZL184 (40mg/kg, once a day, 6 d) reduced the intensity of jumps, 
weight loss and occurrence of diarrhea, but repeated treatment with a low (4mg/kg) dose did not 
have anti-withdrawal effects. The withdrawal signs measured were (A) jumps, (B) paw flutters, 
(C) weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C. **p<0.01, 
*p<0.05 vs. vehicle; ### p<0.001, # p < 0.05 vs. PF-3845; n=11-12 mice/group. 
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Figure 13. FAAH (-/-) mice display attenuated naloxone-precipitated withdrawal signs.   
The withdrawal signs measured were (A) jumps, (B) paw flutters, (C) weight loss and (D) 
diarrhea. Data expressed as mean ± SEM for panels A-C. **p<0.01, *p<0.05 vs. FAAH (+/+) 
group; n=6-7 mice/group. 
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Figure 14. The FAAH inhibitor PF-3845 attenuates a subset of naloxone-precipitated morphine 
withdrawal signs in a CB1 receptor dependent manner. 
 PF-3845 (10 mg/kg, i.p.) reduced the intensity of jumps and paw flutters, which was reversed 
by rimonabant (3 mg/kg, i.p.). The withdrawal signs measured were (A) jumps, (B) paw flutters, 
(C) weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C. **p<0.01, 
*p<0.05 vs. vehicle; ### p<0.001, # p < 0.05 vs. PF-3845; n=11-12 mice/group. 
63 
 
Table 3. Endocannabinoid levels in brain regions associated with opioid withdrawal 
AEA (top) and 2-AG (bottom) levels are not altered following treatment with either morphine 
or placebo and acute challenge with either saline or naloxone (1 mg/kg, s.c.). Data expressed as 
mean ± SEM; p<0.05 v/s Placebo-saline 
 
Treatment 
AEA levels (pmol/g) 
LC PAG Amygdala Ileum 
Placebo-saline 3.7 ± 0.3 4.2 ± 0.3 9.5 ± 0.8 1.2  ± 0.3 
Morphine- saline 5.1  ± 1.0 4.5 ± 0.6 8.2 ± 0.6 1.3  ± 0.2 
Placebo- naloxone 4.7  ± 0.4 4.8 ± 0.5 9.1 ± 1.1 1.5  ± 0.1 
Morphine- naloxone 4.3  ± 0.4 4.6 ± 0.5 8.2 ± 0.6 1.7  ± 0.2 
 
 
2-AG levels (nmol/g) 
LC PAG Amygdala Ileum 
Placebo-saline 6.4 ± 0.4 11.1 ± 0.9 11.6 ± 1.3 5.6 ± 0.7 
Morphine- saline 7.0 ± 0.5 11.8 ± 1.5 10.8 ± 0.9 5.6 ± 1.1 
Placebo- naloxone 6.9 ± 0.7 11.7 ± 2.4 17.7 ± 4.2* 5.8 ± 1.0 
Morphine- naloxone 6.3 ± 0.6 10.2 ± 0.8 17.0 ± 3.6* 6.6 ± 1.9 
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3.6. Discussion 
In these experiments, we report that inhibition of the endocannabinoid catabolic 
enzymes, MAGL or FAAH, reduces naloxone-precipitated withdrawal in an in vivo model of 
morphine dependence. While previous studies have demonstrated that THC and other 
cannabinoid agonists reduce precipitated withdrawal in opiate-dependent rodents (Bhargava, 
1976; Vela et al., 1995; Yamaguchi et al., 2001), this is the first report demonstrating that 
elevating endocannabinoids by blocking their hydrolysis represents a viable approach to reduce 
opioid withdrawal. Acutely administered JZL184, which preferentially inhibits MAGL over 
FAAH and selectively raises brain 2-AG, but not anandamide in vivo (Long et al., 2009a; Long 
et al., 2009b), completely blocked all measured behavioral effects of precipitated withdrawal, 
including paw flutters, jumps, diarrhea, and weight loss. Rimonabant blocked these effects, 
indicating a necessary role of CB1 receptors. On the other hand, the CB2 receptor antagonist 
SR144528 did not block the effects of JZL184 indicating that CB2 receptors are not required for 
its anti-withdrawal effects. Repeated treatment with high doses of JZL184 led to maintenance of 
anti-withdrawal effects. While FAAH (-/-) mice showed a reduction in all three measures of 
naloxone-precipitated withdrawal, PF-3834 reduced only naloxone-precipitated jumping and 
paw flutters, but did not attenuate diarrhea or body weight loss.  
In this set of studies, we have examined the effects of FAAH and MAGL inhibitors on 
naloxone-precipitated opioid withdrawal signs. The precipitated withdrawal model uses an 
antagonist (i.e naloxone) to abruptly halt MOR activation by morphine allowing expression of 
symptoms mimicking that of natural withdrawal. This model offers potential advantages that the 
syndrome is short in duration and the symptoms observed are reliably and overtly quantifiable.  
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The pharmacological effects of JZL184 undergo tolerance in a variety of pain assays 
after repeated treatment at high doses (Schlosburg et al., 2010). Here we report that the anti-
withdrawal effects of high dose JZL184 do not undergo tolerance. This may be due to different 
signaling pathways at the CB1 receptor or distinct neural substrates mediating withdrawal, 
different from those involved in mediating analgesia.  
In our studies, induction of withdrawal in morphine-dependent mice did not alter AEA 
or 2-AG levels in brain areas associated with opiate withdrawal, including LC, PAG, and 
amygdala, though 2-AG levels have been reported to be increased in other brain regions of rats 
treated repeatedly with morphine (Vigano et al., 2003). Likewise, chronic heroin self-
administration in rats does not produce overt CB1 receptor functional changes in LC, PAG, 
amygdala, and other brain structures (Sim-Selley et al., 2000). This pattern of results argues 
against direct activation of the endocannabinoid system during opioid withdrawal.  On the other 
hand, inhibitors of endocannabinoid hydrolysis elevate AEA and 2-AG levels in whole brain 
(Ahn et al., 2009; Long et al., 2009a; Long et al., 2009b) as well as in brain regions associated 
with opiate withdrawal. Thus, MAGL and FAAH inhibitors attenuate the expression of 
withdrawal signs by extending the activity of endocannabinoids at the CB1 receptor.  
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Chapter 4: Effect of inhibition of eCB catabolic enzymes on spontaneous opioid 
withdrawal signs 
In Chapter 3, we have established that inhibitors of endocannabinoid catabolic enzymes 
reduce naloxone-precipitated opioid withdrawal signs. The precipitated withdrawal model is 
widely used because it produces a severe withdrawal response with a quick onset in a short 
duration of time.  The spontaneous withdrawal procedure, on the other hand, more closely 
models the antecedents of withdrawal occurring in opioid addicts, though it has a slower 
throughput than the precipitated withdrawal model. Thus, potential treatments for opioid 
withdrawal are not evaluated for their efficacy in attenuating spontaneous withdrawal signs as 
often as in precipitated withdrawal models. In mice, abrupt cessation of morphine 
administration leads to expression of withdrawal signs similar to that elicited by an opioid 
antagonist. Particularly, platform jumping is commonly observed and considered to be a reliable 
indicator of the induction of withdrawal (Way et al., 1969). These somatic signs last for up to 48 
h, with peak intensity of withdrawal occurring between 6-8 h following cessation of opioid 
administration. This model also allows for examining the anti-withdrawal effects and selecting 
agents that have a sustained half-life throughout the time course of withdrawal. Despite the fact 
that the spontaneous withdrawal procedure presents with considerable challenges, it is 
considered to possess more face validity than precipitated withdrawal procedure for modeling 
human opioid withdrawal.  
In this chapter, we investigated the dose-response relationship of the MAGL inhibitor 
JZL184 to reduce spontaneous withdrawal induced jumps, paw flutters, head shakes, diarrhea 
and weight loss in mice implanted with morphine pellets. In addition, we tested the 
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effectiveness of a combination of low-dose JZL184 and high dose of the FAAH inhibitor PF-
3845 in reducing abrupt morphine withdrawal signs. The selective CB1 receptor antagonist, 
rimonabant was employed to assess cannabinoid receptor involvement of the anti-withdrawal 
effects of JZL184 and the combination. In order to evaluate whether compensatory changes of 
endocannabinoid system occurs following treatment with MAGL and FAAH inhibitors in ICR 
mice, endocannabinoid and arachidonic acid (AA) levels were quantified in whole brain. In 
addition, we measured changes in CB1 receptor number and G-protein activation following 
repeated treatment with these inhibitors.  
Methods 
Subjects  
Male ICR mice (Harlan laboratories; Indianapolis) weighing between 26 and 30 g served 
as subjects. The mice were housed 4-5 per cage in a temperature controlled (20-22
o
C) 
environment, in an American Association for the Accreditation of Laboratory Animal Care-
approved facility. The mice were kept on a 12 h light/ dark cycle, with all experiments being 
performed during the light cycle.  Food and water were available ad libitum.  The study was 
performed with the approval of the Institutional Animal Care and Use Committee at Virginia 
Commonwealth University in accordance with the Guide for the Care and Use of Laboratory 
Animals. 
Drugs 
Morphine pellets (75 mg), placebo pellets, morphine sulfate, THC, and rimonabant were 
obtained from the National Institute on Drug Abuse (Bethesda, MD).  Naloxone hydrochloride 
was purchased from Cayman chemicals (Ann Arbor, MI).  JZL184 and PF-3845 were 
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synthesized as described previously by Organix Inc. (Woburn, MA) (Ahn et al., 2009; Long et 
al., 2009a). THC, PF-3845, JZL184 and rimonabant were dissolved in ethanol, followed by 
addition of Emulphor-620 (Rhone-Poulenc, Princeton, NJ), and diluted with 0.9% saline to form 
a vehicle mixture of ethanol:emulphor:saline in a ratio of 1:1:18. Naloxone and morphine were 
dissolved in 0.9% saline.  All injections were administered in a volume of 0.01 ml per 1 g body 
weight.  THC and naloxone were administered via subcutaneous (s.c.) injection, whereas PF-
3845, JZL184 and rimonabant were given via intraperitoneal (i.p.) injection.  For spontaneous 
withdrawal studies all treatments were given 1 h before the first test time-point. 
Morphine pellet implantation surgery  
In order to induce opioid dependence, mice were implanted with morphine pellets as 
previously described (Way et al., 1969).  After induction of anesthesia with 2.5% isoflurane, the 
fur was shaved, the skin was disinfected with a sterile betadine swab (Purdue products, 
Stamford, CT), and a 1 cm horizontal incision was made in the midscapular region, using sterile 
surgical scissors.  A 75 mg morphine sulfate pellet was inserted subcutaneously, and the 
incision was closed with a sterile staple.  The mice were allowed to recover in heated home 
cages for 1 h after surgery and then returned to the vivarium until testing. 
Spontaneous morphine withdrawal  
In withdrawal experiments, mice were implanted with 75 mg morphine pellets.  Approximately, 
71 h after pellet implantation, mice were weighed and assessed for baseline withdrawal 
behavior. The pellets were removed under light isoflurane anesthesia approximately 72 h after 
implantation. The mice were housed individually in cages that were placed on heating pads for 
2 h. At 1 h after pellet removal, groups received an injection of drug or vehicle.  The animals 
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were observed for spontaneous withdrawal signs for 15 min intervals at 2, 4, 6 and 8 h post-
pellet removal. The mice continued to be housed singly throughout the testing period, and food 
and water were available ad libitum, except during the 15 min observation periods. Spontaneous 
withdrawal signs were quantified using a procedure that was adapted from Way et a. (1969). 
The percentage of mice that jumped off a circular platform (15 cm diameter x 70 cm height), the 
total number of paw tremor and head shake incidences, and body weight were recorded at each 
time point. Paw flutters and head shakes were each pooled across all time points to represent the 
total number of incidences of the behaviors observed. The percentage of mice presenting with 
diarrhea across the 8 h test session was also recorded. Finally, the mice were weighed at the end 
of each testing period.  
Behavioral assessment of cannabinoid activity  
For this study mice were injected with either vehicle (JZL184 40 mg/kg or PF3845 10 mg/kg, 
i.p.) on the sixth day (single groups), or drug (JZL184 40 mg/kg, JZL184 4mg/kg,  PF3845 10 
mg/kg, or JZL184 4 mg/kg + PF-3845 10 mg/kg i.p.). Catalepsy was evaluated using the bar 
test, in which the front paws of each subject were placed on a rod (0.75 cm diameter) that was 
elevated 4.5 cm above the surface. Mice were timed if they remained motionless with their 
paws on the bar (with the exception of respiratory movements), and the time motionless from 3 
attempts to place on the bar were totaled with a cutoff of 60 s. Hyper-reflexive popping and 
jumping away from the bar was also scored. In the tail immersion test, each mouse was placed 
head first into a small bag fabricated from absorbent under pads (VWR Scientific Products; 4 
cm diameter, 11 cm length) with the tail out of the bag. The experimenter gently held the mouse 
and immersed approximately 1 cm of the tip of the tail into a water bath maintained at 52.0°. 
The latency for the animal to withdraw its tail from the water within a 10s cutoff time was 
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scored. Rectal temperature was determined by inserting a thermocouple probe 2.0 cm into the 
rectum and temperature was obtained from a telethermometer. Before any injections, baseline 
tail nociceptive latencies and rectal temperatures were assessed for all tests.  
Agonist-stimulated [
35S]GTPγS binding  
Mice were sacrificed by decapitation, and the whole brain, minus olfactory bulbs, was removed. 
Tissues were stored at -80°C until use. Samples were placed in 5 ml of cold membrane buffer 
(50 mM Tris-HCl, 3 mM MgCl2, 1 mM EGTA, pH 7.4) and homogenized. Homogenized 
samples were centrifuged at 50,000g at 4°C for 10 min. The supernatant was removed and 
samples were resuspended in 5 ml of assay buffer A (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM 
EGTA, 100 mM NaCl, pH 7.4). Protein concentration was determined by the Bradford method 
(Bradford, 1976). To reduce basal activation by adenosine receptors, preincubation for 15 min 
at 30°C with adenosine deaminase (3 mU/ml) in assay buffer was performed before addition to 
the final buffer mixture. Concentration-effect curves were generated by incubating 5 μg of 
membrane protein in assay buffer B (assay buffer A plus 1.25 g/l BSA), with 3 nM to 3 μM 
CP55,940, 30 μM GDP, and 0.1 nM [35S]GTPγS in 0.5-ml total volume. Solutions were 
vortexed and to incubated for 2 h at 30°C. Basal binding was measured in the absence of 
agonist, and nonspecific binding was measured in the presence of 20 μM unlabeled GTPγS. The 
reaction was terminated by vacuum filtration though Whatman GF/B glass fiber filters, 
followed by three washes with 4°C Tris buffer (50 mM Tris-HCl, pH 7.4). Bound radioactivity 
was determined by liquid scintillation spectrophotometry at 95% efficiency after 10-h extraction 
in ScintiSafe Econo 1 scintillation fluid.  
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[
3
H]-SR141716A binding  
Membranes were prepared as described above. Membrane proteins (10 μg) were incubated with 
0.1-2.5 nM [
3
H]-SR141716A in 50 mM Tris-HCl, 3 mM MgCl2 , 0.2 mM EGTA, 100 mM 
NaCl, 1.25 g/L BSA, pH 7.4 in the presence or absence of 5 μM unlabeled rimonabant (to 
determine non-specific binding) for 90 min at 30°C. The reaction was terminated by vacuum 
filtration though Whatman GF/B glass fiber filter that was pre-soaked in Tris buffer containing 
5 g/L BSA (Tris-BSA), followed by three washes with 4°C Tris-BSA. Bound radioactivity was 
determined by liquid scintillation spectrophotometry at 45% efficiency after extraction in 
ScinitSafe Econo 1 scintillation fluid.  
Statistical analysis  
All data are reported as mean ± SEM. In the behavioral experiments, non-continuous 
behaviors, including head shakes and paw tremors, are presented as counted observations.  The 
occurrence of jumps and diarrhea was scored as a binary event for the entire 15 min period for 
each time point. Weight loss (g) was calculated by subtracting the body weight at the conclusion 
of each 15 min observation period from the pre-pellet removal weight. Data were analyzed 
using one-way or two-way between measures analysis of variance (ANOVA), followed by 
Dunnett’s or Scheffe’s post hoc test. The percentage of mice between groups presenting with 
diarrhea and percentage of mice that jumped off platforms were compared by the z test of two 
proportions.   
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Results 
4.1. Abrupt removal of morphine pellet induces opiate withdrawal signs in mice 
As shown in Figure 15, morphine pellet removal increased the percentage of mice 
jumping from the platform (4-8 h; p<0.05; Fig 15A), increased the incidences of paw flutters (2-
24 h; p<0.05; Fig 15B) and head shakes (2-24 h; p<0.05; Fig 15C), and resulted in greater 
weight loss (4-24 h; p<0.05; Fig 15 D) compared to mice that had placebo pellets removed. 
Morphine pellet removal also resulted in diarrhea (Fig 15E).  
4.2. JZL184 dose-dependently attenuates spontaneous withdrawal signs in a CB1-dependent 
manner 
In order to examine whether MAGL inhibition reduces spontaneous withdrawal signs, we 
treated morphine-pelleted mice with either vehicle or JZL184 (4, 16, or 40 mg/kg, i.p.). Both 40 
and 16 mg/kg JZL184 significantly reduced jumping at 4, 6 and 8 h post-pellet removal (Fig. 
16A). JZL184 dose-responsively reduced the intensity of total paw flutters [F(3,28) = 26.4; p < 
0.001; Fig. 16B], total head shakes [F(3,28) = 12.1; p < 0.001; Fig. 16C ], and weight loss 
across all time points [F(12, 112) = 4.0; p < 0.001; Fig. 16D].  All doses of JZL184 completely 
blocked the occurrence of diarrhea in morphine-dependent mice undergoing withdrawal (Fig. 
16E).  
We next evaluated whether the anti-withdrawal effects of JZL184 were mediated by the 
CB1 receptor. An additional group of mice was co-administered JZL184 (40 mg/kg) and 
rimonabant (3mg/kg, i.p).  Rimonabant reversed the anti-withdrawal effects of JZL184, as 
indicated by the increased percentage of spontaneous withdrawal jumps (Fig. 16A), number of 
total paw flutters [F(2,22) = 24.8; p < 0.001; Fig. 16B], number of  total head shakes [F(2,22) = 
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9.7; p < 0.001; Fig. 16C] and intensity of weight loss [F(8,84) = 5.3; p < 0.001; Fig. 16D]. In 
addition, rimonabant also reversed the anti-diarrheal effects of JZL184 (Fig 16E). 
4.3. The FAAH Inhibitor PF-3845 and THC also reduce the intensity of abrupt withdrawal 
signs 
To elucidate the role of FAAH in morphine withdrawal, we evaluated the irreversible FAAH 
inhibitor, PF-3845 (10 mg/kg, i.p.) on spontaneous morphine withdrawal.  PF-3845 significantly 
attenuated the frequency of paw flutters [p < 0.001; Fig 17B] and head shakes [p < 0.001; Fig 
17D], but did not affect jumping behavior, weight loss or the expression of diarrhea (Fig 17A, 
17D and 17E). The phytocannabinoid THC blocked withdrawal induced jumping (Fig 17A), 
reduced the intensity  of total paw flutters [p < 0.001; Fig 17B], head shakes [p < 0.01; Fig 17C] 
and weight loss [F(4,52) = 3.966; p < 0.01; Fig. 17D], and completely prevented the occurrence 
of diarrhea (Fig. 18E). This experiment shows that acute FAAH inhibition attenuates a subset of 
withdrawal signs (i.e., paw flutters and head shakes), while the cannabinoid receptor agonist 
THC attenuates all the measured behavioral signs. 
4.4. Combined partial MAGL inhibition and complete FAAH inhibition attenuates 
spontaneous withdrawal signs through the activation of CB1 receptors 
To evaluate the role of dual inhibition of MAGL and FAAH on spontaneous opioid withdrawal 
signs a set of mice was co-administered a low dose of JZL184 (4 mg/kg, i.p.) or vehicle and a 
high dose of PF-3845 (10 mg/kg, i.p.) or vehicle. These doses were selected to optimize the 
anti-opioid withdrawal effects of endocannabinoid catabolic inhibitors and avoid the 
dependence potential of high doses of JZL184. Combination of JZL184 and PF-3845, but not 
either drug alone, significantly reduced jumping at 4, 6, and 8 h after morphine pellet removal 
(Fig. 18A).  In addition, the combination as well as each drug by itself significantly reduced the 
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intensity of total paw flutters [F(3,26) = 12.3; p < 0.001; Fig. 18B] and head shakes [F(3,26) = 
4.4; p < 0.01; Fig. 18C ]. However, only the combination reduced the intensity of weight loss 
[F(12,104) = 1.7; p < 0.01; Fig. 18D], as indicated by significant interactions between group and 
time. In addition, the combination treatment significantly blocked the occurrence of diarrhea 
while the groups treated with either drug alone presented with diarrhea (Fig. 18E). Either 
individual treatment reduced only the intensity of paw flutters and head shakes, whereas the 
combination reduced the full spectrum of abrupt withdrawal signs. 
 Rimonabant completely blocked the anti-withdrawal effects of combined administration 
of JZL184 and PF-3845, indicating a CB1 receptor mechanism of action. Rimonabant co-
treatment completely reversed the effects of the combination as indicated by a significant 
interaction for paw flutters [F(1,37); p<0.01, Fig 19B], head shakes [F(1,37); p<0.05; Fig 19C] 
and weight loss [F(12,108)=2.752; p<0.01; Fig 19D]. In addition, rimonabant also reversed the 
effects of the combination in blocking jumps and the occurrence of diarrhea (Fig 19A & E). 
75 
 
 
Figure 15. Evaluation of spontaneous withdrawal signs in mice.  
Removal of morphine pellets leads to increased spontaneous withdrawal signs compared to 
mice implanted with placebo pellets. (A) Percentage of mice that displayed platform jumping, 
(B) number of paw flutters, (C) number of head shakes, (D) weight loss and (E) expression of 
diarrhea. Data expressed as mean ± SEM for panels B-D. *p<0.05,**p<0.01,***p<0.001 vs. 
placebo; n = 6-9 mice/group. 
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Figure 16. JZL184 reduces spontaneous withdrawal signs in a CB1-dependent manner 
The MAGL inhibitor JZL184 dose-dependently attenuates the intensity of the following 
spontaneous withdrawal signs in morphine-dependent mice through the activation of CB1 
receptors. Rimonabant (3 mg/kg) when co-administered with JZL184 (40mg/kg) blocked it anti-
withdrawal effects. The withdrawal signs measured include (A) jumps, (B) paw flutters, (C) 
head shakes, (E) weight loss and (E) diarrhea. Data expressed as mean ± SEM for panels B-D. 
*p<0.05 vs. morphine control; # p<0.05 v/s JZL184 treated group; n = 7-9mice/group. 
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Figure 17. THC and PF-3845 reduce spontaneous withdrawal signs 
The phytocannabinoid THC attenuates the intensity of the spontaneous withdrawal signs in 
morphine-dependent mice while the FAAH inhibitor PF-3845 reduces the intensity of some 
withdrawal signs. The withdrawal signs measured include (A) jumps, (B) paw flutters, (C) head 
shakes, (E) weight loss and (E) diarrhea. Data expressed as mean ± SEM for panels B-D. 
*p<0.05 vs. morphine control; n = 7-8 mice/group. 
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Figure 18. Combination of low-dose JZL184 and high-dose PF-3845 reduces abrupt withdrawal 
signs 
The combination of low dose of the MAGL inhibitor JZL184 (4 mg/kg) and high dose of the 
FAAH inhibitor PF-3845 (10 mg/kg) reduces the intensity of the spontaneous withdrawal signs 
in morphine dependent mice to a greater extent than either inhibitor by itself. The withdrawal 
signs measured include (A) jumps, (B) paw flutters, (C) head shakes, (E) weight loss and (E) 
diarrhea. Data expressed as mean ± SEM for panels B-D. *p<0.05 vs. morphine control; n = 7-
8mice/group.  
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Figure 19: Effects of the combination of partial MAGL and complete FAAH inhibition are CB1 
mediated 
Rimonabant blocks the effects of the combination of low dose of the MAGL inhibitor JZL184 
(4 mg/kg) and high dose of the FAAH inhibitor PF-3845 (10 mg/kg) in reducing the intensity of 
the spontaneous withdrawal signs in morphine dependent mice. The withdrawal signs measured 
include (A) jumps, (B) paw flutters, (C) head shakes, (E) weight loss and (E) diarrhea. Data 
expressed as mean ± SEM for panels B-D. *p<0.05 vs. morphine control; n = 10-11 mice/group.  
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4.5. Evaluation of tetrad effects and measurement of endocannabinoid levels in brain 
following acute MAGL and FAAH inhibition 
Mice treated acutely with either vehicle, THC (10 mg/kg), low-dose JZL184 (4 mg/kg), 
PF-3845 (10 mg/kg), combination of low-dose JZL184 + PF-3845 and high-dose JZL184 (40 
mg/kg) were assessed in the tetrad assay (Table 4). After assessment of tetrad effects, brains 
were harvested at 2h post-injection. Neither treatment produced any change in the open field 
locomotor behavior or cataleptic effects in ICR mice. Additionally, only THC produced 
significant hypothermia (ΔoC= -2.02 ± 0.7; p<0.05) and antinociception (Δ sec= 2.21 ± 0.9; 
p<0.05) in the tail withdrawal test, while the other treatments had no effect.  
The elevation of whole-brain endocannabinoid levels following acute and prolonged 
MAGL and FAAH inhibition by JZL184 and PF-3845 has been previously established in 
C57BL/6J mice (Long et al., 2009a; Schlosburg et al., 2010). Additionally, MAGL inhibition 
reduces AA levels in the brain which is a hydrolytic product of 2-AG catabolism. A recent 
report suggests that 2-AG hydrolysis by MAGL is responsible for up to 80% of AA generated in 
the brain (Ahn et al., 2009; Long et al., 2009a; Nomura et al., 2011). To determine whether 
acute treatment with MAGL and FAAH inhibitors produces altered levels of endocannabinoids 
and arachidonic acid in whole brains from ICR mice we measured the levels of AEA, 2-
AG,OEA, PEA and AA. Acute treatment with low-dose JZL184 (4 mg/kg), alone and in 
combination with FAAH inhibition, significantly elevated 2-AG levels 2-4 fold [F(3,28) = 25.7; 
p<0.001; Fig.20A]. Notably, mice treated with the combination showed a higher elevation in 2-
AG than mice treated with JZL184 (4mg/kg) alone. High-dose JZL184 elevated 2-AG levels 
approximately 10 fold (p<0.001 v/s vehicle control. Fig. 19A), comparable to levels observed in 
C57BL/6J mice (Long et al., 2009b). Acute treatment with high-dose JZL184 led to 
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approximately 40% decrease in AA levels (p<0.05) and the combination moderately lowered 
AA levels [F(3,28) = 4.6; p<0.01, Fig. 20B] compared to vehicle controls. When examining 
endocannabinoid accumulation in brain 2 h following acute treatment with PF-3845 or 
combination of PF-3845+JZL184, AEA was elevated more than 8-fold above that of vehicle 
[F(3,28)=309.3; p<0.001; Fig 20C)].  
4.6. Brain CB1 receptors are impaired by prolonged MAGL, but not FAAH blockade  
Genetic or prolonged pharmacological disruption of MAGL, but not FAAH, leads to 
down-regulation and desensitization of CB1 receptors in C57BL/6J mice (Falenski et al., 2010; 
Schlosburg et al., 2010). To determine whether these CB1 adaptations also occurred in outbred 
ICR mice, we measured endocannabinoid and AA levels, examined CB1 receptor expression 
and function through specific binding of [
3
H]-SR141716A and CP55,940-stimulated [
35
S]-
GTPγS binding, respectively, in whole-brain homogenates from mice treated with either 
vehicle, low-dose JZL184 (4 mg/kg), PF-3845 (10 mg/kg), combination of JZL184 (4mg/kg) + 
PF-3845 (10mg/kg), or high-dose JZL184 (40 mg/kg). Mice were treated with inhibitors/vehicle 
once a day for 5 days and brains were harvested 24 h later or once a day for 6 days and brains 
extracted 2 h later. 
Repeated low dose JZL184 did not lead to increased levels of 2-AG at 24 h, though high 
dose JZL184 increased brain 2-AG levels at this time point approximately 8 fold compared to 
vehicle (p<0.001; Fig. 21A). Repeated treatment with high-dose JZL184 led to about 40% 
decrease in AA levels (p<0.05) and the combination moderately lowered AA levels [repeated 
treatment, F(3,20)= 3.7; p<0.05, Fig. 21B] compared to vehicle controls. On the contrary, low 
dose JZL184 elevated 2-AG levels, at 2 h following repeated dosing, approximately 10 fold 
while the combination elevated 2-AG 8-fold [F(4,24)=62.445; p<0.001; Fig. 20D]. These 
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treatments also significantly attenuated AA levels by approximately 40%. The high dose of 
JZL184 elevated 2-AG levels almost 20-fold and produced about 70% decrease in AA levels 
[F(4,24) = 19.5; p<0.05, Fig. 21E] compared to vehicle controls. Neither low dose nor high dose 
of repeated JZL184 injections produced significant increases in whole brain AEA levels at 2 h 
or 24 h (Fig. 21 C & F). Prolonged FAAH blockade did not induce changes in AEA or 2-AG 
levels 24 h post treatment. Prolonged FAAH inhibition with or without concomitant MAGL 
inhibition led to elevated AEA levels at 2 h similar to acute treatment [F(4,24)=46; p<0.001; Fig 
21F].   
Consequently, the CP55,940-stimulated [
35
S]-GTPγS concentration-effect curves (Fig. 
22 A and B) display a substantial reduction in Emax of 44% from mice receiving repeated  high 
dose-JZL184 (40 mg/kg). Two-way ANOVA analysis shows that there is a significant 
attenuation of Emax by JZL184 (4 mg/kg) treatment irrespective of simultaneous FAAH 
inhibition [F(1,20)=11.9; p<0.01; Fig.22A]. Nonlinear sigmoidal regression on the activation 
curves revealed a significantly lower maximal efficacy of agonist stimulation (Emax). Repeated 
treatment with high dose-JZL184 (40 mg/kg) also resulted in decreases in whole brain CB1 
receptor binding curves compared to vehicle. The non-linear regression of the binding data 
revealed a significantly reduced maximal binding (Bmax) by 38% compared to vehicle (Fig 22C 
and D). None of the other treatments significantly altered whole brain CB1 receptor binding 
levels. Thus, prolonged complete MAGL inhibition leads to both down-regulation and 
desensitization of CB1 receptors in whole brain. Low dose JZL184 alone or in combination with 
FAAH inhibition resulted in receptor desensitization in the absence of apparent receptor loss.  
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Table 4. Tetrad effects of MAGL and FAAH inhibitors in ICR mice 
Treatment 
(mg/kg) 
Hypothermia 
(ΔoC) 
Tail flick latency 
(Δ sec) 
Catalepsy 
(sec) 
Time Immobile 
(sec) 
Vehicle 0.46 ± 0.3  -0.23 ± 0.2  0.00  11.2 ± 1.5  
 JZL184 (4)  0.19 ± 0.3  0.01 ± 0.1  0.00  9.72 ± 2.9  
PF-3845 (10)  0.18 ± 0.2  0.10 ±  0.2  0.00  10.7 ± 1.8  
JZL(4) + PF(10)  0.31 ± 0.2  -0.26 ± 0.2  0.00  19.1 ± 7.0  
JZL184 (40)  -0.70 ± 0.4  1.19 ± 0.8  0.00  14.6 ± 3.2  
THC (10)  -2.02 ± 0.7*  2.21 ± 0.9*  9.05 ± 6  23.6 ± 16  
Data represented as mean ± SEM; *p<0.05 v/s vehicle control; n=9/group 
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Figure 20: Whole brain levels of endocannabinoids and arachidonic acid in mice with acutely 
disrupted MAGL and/or FAAH.  
Levels of (A) 2-AG, (B) arachidonic acid, and (C) AEA in the whole brain from mice treated 
acutely (single dose i.p. evaluated  2 h later) treated with either vehicle, low-dose JZL184(4 
mg/kg), PF-3845 (10 mg/kg), combination of JZL184(4mg/kg) + PF-3845(10mg/kg) and high-
dose JZL184(40 mg/kg).  Data expressed as mean ± SEM. *p<0.05; **p<0.01, ***p<0.001 vs. 
vehicle control; n=8 mice/group.  
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Figure 21. Whole brain levels endocannabinoids and arachidonic acid from mice repeatedly 
treated with MAGL and/or FAAH inhibitors.  
Levels of AEA, 2-AG and AA ( treatment: 5 d, one dose per day (i.p.), and evaluated 24 h after 
final dose; Panel A-C) and ( treatment: 6 d, one dose per day (i.p.), and evaluated 2 h after final 
dose; Panel D-F). Data expressed as mean ± SEM. *p<0.05; **p<0.01, ***p<0.001 vs. vehicle 
control; n=6 mice/group.  
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Figure 22. CB1 receptor function in mice following prolonged disruption of MAGL and/or 
FAAH.  
CP55,940-stimulated [
35
S]-GTPγS binding as indicated by (A)  best fit E max and (B) mean % 
stimulation of CP55,940 concentration curve; Membrane-specific CB11 receptor binding by the 
antagonist [
3
H]-SR141716A, as evaluated by the (C) best-fit Bmax of binding curves and (D) 
specific binding curves, from whole brain homogenates from mice repeatedly treated with 
MAGL and/or FAAH inhibitors (treatment: 5 d, one dose per day (i.p.), and evaluated 24 h after 
final dose. Data represented as mean ± SEM.  *p<0.05; **p<0.01, ***p<0.001 vs. vehicle 
control; n=6 mice/group.  
87 
 
4.7. Discussion 
Acutely administered JZL184, which selectively raises brain 2-AG, but not anandamide in 
vivo (Long et al., 2009a, Long et al., 2009b), completely blocked all measured behavioral 
effects of spontaneous withdrawal, including paw flutters, head shakes, jumps, diarrhea, and 
weight loss. The FAAH inhibitor PF-3845 reduced only spontaneous withdrawal-induced paw 
flutters and head shakes, but did not attenuate intensity of jumps, diarrhea or body weight loss. 
Furthermore, combination of low-dose JZL184 and high dose of the FAAH inhibitor PF-3845 
significantly attenuated all measured signs of spontaneous withdrawal. Rimonabant blocked 
these effects, indicating a necessary role of CB1 receptors.  The combination elevated 
appropriate levels of AEA and 2-AG and did not produce any cannabinoid tetrad effects.  
However, repeated treatment of the combination led to CB1 receptor desensitization. 
The observation that complete MAGL inhibition significantly blocked all opioid withdrawal 
symptoms, while FAAH inhibition only reduced a subset of these effects corroborates with our 
previous findings in the precipitated withdrawal model (Ramesh et al., 2011a) (see Chapter 3). 
However, the ability of prolonged MAGL inhibition at high doses of JZL184 to elicit 
cannabinoid dependence represents a drawback of using these inhibitors in treatment of abuse 
disorders (Schlosburg et al., 2010). Alternatively, a combination of low-dose JZL184 (4 mg/kg) 
and PF-3845 (10 mg/kg) possessed nearly full efficacy in attenuating physical opiate 
withdrawal signs. The magnitude of these effects was comparable to that of complete MAGL 
inhibition (40 mg/kg) and augmented in comparison to low-dose JZL184 (4 mg/kg) or PF-3845 
(10 mg/kg) alone. The doses of PF-3845 and JZL184 selected for combination were intended to 
maximize the therapeutic efficacy of inhibiting both enzymes while avoiding the undesirable 
side-effects of complete MAGL inhibition. This combination also produces augmented anti-
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allodynic effects in the carrageenan pain assay (Wise, Kinsey et al, unpublished data) and 
repeated treatment does not lead to functional CB1 receptor adaptations in C57BL/6J mice.  
In these experiments, we stimulated CB1 receptors by elevating endogenous cannabinoid 
through the use of inhibitors of their hydrolytic enzymes. We quantified brain levels of 
endocannabinoids following acute repeated treatment of JZL184, PF-3845, and combined 
JZL184+PF-3845. Notably, the combination of partial MAGL/complete FAAH inhibition 
acutely resulted in approximately 2-fold higher levels of 2-AG compared to partial MAGL 
inhibition by itself. FAAH blockade by itself did not alter 2-AG levels compared to control 
levels.The enhanced elevation produced by the combination may be due to the ability of FAAH 
to degrade 2-AG (Blankman et al., 2007). To test this idea, we could examine whether PF-3845 
further inhibits 2-AG hydrolysis activity in brain tissue from ICR mice treated with JZL184. 
Additionally, it would be necessary to determine if the enhanced elevation is observed in all 
relevant brain regions (ex. cerebelleum, LC, nucleus accumbens, striatum, PAG) or restricted to 
a specific area.   
In a clinical setting, therapeutic agents used to manage of opiate withdrawal would likely be 
given repeatedly; therefore, it is important to compare the impact of repeated administration of 
compounds on endogenous cannabinoid levels as well as to assess CB1 receptor function. 
Repeated administration of 40 mg/kg JZL184 elevated 2-AG whole brain levels 24 h after the 
last injection. These results are in agreement with studies in C57BL/6J mice in which repeated 
MAGL blockade resulted in up to 12-fold elevations in 2-AG up to 26 h after the last exposure 
of JZL184 (Schlosburg et al., 2010). Repeated JZL184 treatment results in more prolonged 
inhibition of MAGL and greater 2-AG levels than that produced by an acute injection. The 
further increase in 2-AG levels following repeated treatment is probably due to delayed 
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recovery of MAGL due to the long half-life of JZL184.  Accordingly, repeated administration 
of high dose JZL184 also produced significant losses in the maximal stimulation of CB1 
receptors in whole brain by the cannabinoid receptor agonist CP55,940. Loss of maximal 
activation is usually indicative of desensitization of receptors, in which GRK phosphorylation 
and β-arrestin binding prevents typical activation in the presence of ligand. However, given that 
the magnitude of loss in receptor activation almost exactly equals the loss of receptor binding 
sites in almost all cases, it appears that prolonged 2-AG elevation with high-dose JZL184 
promotes significant receptor internalization and degradation. However, repeated treatment with 
low-dose JZL184 treatment alone or in combination with PF-3845 did not lead to changes in 2-
AG levels 24 h post-final injection, suggesting that the levels of 2-AG are normalized over the 
course of repeated treatment. We confirmed this observation this observation by also examining 
an earlier time point (i.e. 2h) following the final injection of the inhibitors. Accordingly, these 
groups showed CB1 receptor desensitization, but no changes in CB1 receptor number in whole 
brain. Repeated FAAH inhibition did not lead to accumulation of AEA levels 24h after the last 
dose. Thus, FAAH inhibition produces a transient elevation of AEA that does not accumulate in 
the brain following repeated treatment. These results confirm previous findings that prolonged 
complete MAGL inhibition leads to acculmulation of brain 2-AG and reduction of AA levels 
(Schlosburg et al., 2010). Taken together, these findings indicate that the moderate elevations in 
2-AG produced by low-dose JZL184, as well as the combination (2-4 fold), induced 
desensitization of CB1 receptors, but was insufficient to produce receptor down-regulation. 
However, given that cannabinoids induce region-dependent changes in CB1 receptor function 
(Breivogel et al., 1999; Schlosburg et al., 2010), regional differences may not be reflected in 
whole brain homogenate binding. 
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Chapter 5:  Anti-diarrheal actions of MAGL inhibition: Effects on naloxone-precipitated 
hypermotility and hypersecretion in morphine-dependent ilea 
In both the naloxone-precipitated morphine withdrawal and spontaneous morphine 
withdrawal models, MAGL inhibition, but not FAAH inhibition, blocked the occurrence of 
diarrhea in morphine-dependent mice. The antecedents for diarrhea include increased muscle 
contractility and hypersecretion of fluids and electrolytes in the intestinal tract. In this Chapter, 
we employed the isolated ileum preparation to investigate the mechanism by which JZL184 
blocked diarrhea.  Ileum was exposed to morphine for 1 h at which time naloxone was added to 
the tissue bath to precipitate contractions and hypersecretion. The ileum offers a useful in vitro 
model to investigate opioid withdrawal (Paton, 1957), since it shows tolerance and withdrawal 
to prolonged application of morphine. The cannabinoid receptor agonists THC and WIN-55,212 
have been shown to reduce naloxone-precipitated contractions in ilea subjected to prolonged 
morphine exposure (Frederickson et al., 1976; Basilico et al., 1999).  
Intestinal motility is mediated predominantly by longitudinal muscle, which is 
innervated by the myenteric plexus, while secretion is controlled by the submucosal plexus 
innervating the mucosa and the submucosa (for cross-section of the ileum see Fig. 23). CB1 
receptors are believed to be located enteric neurons and extrinsic primary afferent nerves in the 
submucosa of ileum. Furthermore, primary afferent nerves that express the CB1 receptor 
predominantly innervate regions of the submucosal ganglia where cholinergic 
secretomotoneurons are located (MacNaughton et al., 2004). In addition, MAGL mRNA and 
protein is expressed abundantly in the submucosal plexus of the rat ileum (Duncan et al., 2008). 
MORs are also abundantly expressed in the myenteric and submucosal plexus of the ileum and 
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control muscle contractility and secretion/absorption of electrolytes by modulating Ach release 
(Paton, 1957; Sheldon et al., 1990; Bagnol et al., 1997). In these experiments, we investigated 
whether JZL184 and PF-3845 would ameliorate naloxone-precipitated contractions and 
secretion in morphine-exposed ilea. 
 
Figure 23: Cross-section of ileum 
Outer-inner layers; Serosa, longitudinal muscle, circular muscle, submucosa amd mucosa. 
Muscular layers are innervated by myenteric plexus while submucosa and mucosa receive 
innervations from the submucosal plexus. Cannabinoid and opioid receptors are predominantly 
located in the neuronal tissue. 
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5.1. Methods 
Subjects 
For EFS studies and studies measuring levels of endogenous ligands, male ICR mice 
were used as subjects (Harlan laboratories; Indianapolis). The mice weighed between 26 and 30 
g and were housed 4 per cage in a temperature controlled (20-22
o
C) environment, in an 
American Association for the Accreditation of Laboratory Animal Care-approved facility. The 
mice were kept on a 12 h light/ dark cycle, with all experiments being performed during the 
light cycle.  Food and water were available ad libitum.  The study was performed with the 
approval of the Institutional Animal Care and Use Committee at Virginia Commonwealth 
University in accordance with the Guide for the Care and Use of Laboratory Animals. 
For Ussing Chamber studies female C57BL/6J as well as female CB1 (-/-) and (+/+) 
mice backcrossed onto a C57BL/6J background for at least 13 generations were used as 
subjects. The mice weighed between 18-22g and were housed 4 per cage in a temperature 
controlled (20-22
o
C) environment, in an American Association for the Accreditation of 
Laboratory Animal Care-approved facility. The mice were kept on a 12 h light/ dark cycle, with 
all experiments being performed during the light cycle.  Food and water were available ad 
libitum.  The study was performed with the approval of the Institutional Animal Care and Use 
Committee at the University of Maryland at Baltimore in accordance with the Guide for the 
Care and Use of Laboratory Animals. 
Isometric tension recording 
Previously described methods to assess effects of opioids on longitudinal ileal muscle 
were employed in the present study (Ross et al., 2008). One-centimeter segments of ilea were 
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dissected, flushed of their contents, and trimmed of mesentery.  These preparations were 
suspended in the axis of the longitudinal muscle tied to a glass hook under 1 g passive tension in 
15 ml of siliconized organ baths containing Krebs solution (118 mM NaCl, 4.6 mM KCl, 1.3 
mM NaH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM glucose, and 2.5 mM CaCl2), 
maintained at 37°C and bubbled with 95% O2 and 5% CO2.  Tissues were allowed to equilibrate 
for 60 min before start of experiments, with Krebs solution changed every 15 min.  Isometric 
contractions were recorded by a force transducer (GR-FT03; Radnoti, Monrovia, CA) 
connected to a computer using Acqknowledge 382 software (BIOPAC Systems, Inc., Santa 
Barbara, CA).  The tissues were incubated with 10µM morphine sulfate for 30 min following a 
30 min incubation with either JZL184 (1 µM) or PF-3845 (1 µM).  Naloxone hydrochloride (30 
µM) was then added to the organ bath to precipitate contractions. Contractions to 80 mM 
potassium chloride buffer at the end of the study were used as the reference.  
Neurogenic contractions by transmural field stimulation 
Electric field stimulation (FS, 20V, 7.5 Hz) was applied through concentric electrodes 
over ileal longitudinal muscles.  JZL184 (1 µM) or PF-3845 (1 µM) and/or rimonabant (100nM 
) was added over FS contractions/ relaxations to determine their effects on the neurogenic 
responses. 
Measurement of electrogenic ion transport in vitro in Ussing’s chambers. 
Small intestinal tissue (including neuromuscular layer; whole SI except the proximal 
jejunum) was mounted in Ussing chambers 0.126 cm
2
 of tissue to 5 ml Krebs buffer containing 
10 mM glucose (serosal buffer) and 11.2 mM mannitol (mucosal buffer). The buffer was 
maintained at 37
o
C and continuously aerated 95% oxygen, 5% carbon dioxide. Agar-salt 
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bridges and electrodes were used to measure potential difference. Every 50 s, the tissues were 
short circuited at 1 V (DVC 1000 voltage clamp; World Precision Instruments, Sarasota, FL), 
and the short circuit current (Isc) was continuously monitored.  
To test the reactivity/viability of the tissue a high concentration of glucose is applied to 
the mucosal level to activate the co-transporter which results in an increased short-circuit 
current. Next, the tissue is washed and the glucose and mannitol buffers are applied at the 
serosal and mucosal side respectively. Once the short-circuit current (Isc) reaches a stable 
baseline, morphine (30µM) is applied to the serosal side. Tissues that do not show an acute 
decrease in Isc in response to morphine treatment are not included in the study. After 20 
minutes, the buffer is replaced and morphine is applied again. Ten minutes later JZL184 
(10 µM) or vehicle (DMSO) is applied to the serosal side. Ten minutes later, the tissue is 
washed again and morphine and JZL184/DMSO is immediately re-applied to the tissue. Twenty 
minutes later naloxone is applied to the serosal side of the tissue (30µM) to precipitate 
withdrawal. 
Extraction and quantification of ileum endocannabinoid and prostaglandin levels via LCMS  
In this set of experiments, endocannabinoid, arachidonic acid, and prostaglandin levels 
were quantified in ileum after either in vivo or in vitro application of JZL184.  In the first 
experiment, mice were treated with either JZL184 (40 mg/kg) or vehicle and their ilea were 
harvested 2 h later. In the second experiment, ilea were harvested and the tissue was allowed to 
equilibrate in Krebs buffer for 30 min followed by incubation with either 100nM JZL184 (in 
DMSO) or vehicle for 30 min. The tissues were frozen in dry ice and stored at -80
o 
C. Tissues 
were weighed and subsequently sheered with a tissue disruptor followed by sonication in 6 ml 
of 1:1 v/v hexane:ethyl acetate and 2 ml of Tris buffer (pH 8.0) containing dodecylglycerol (10 
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nmol) and pentadecanoic acid (10 nmol) as internal standards for positive and negative mode 
ionization, respectively. Samples were centrifuged at 2000 g for 5 min and the organic layer 
was removed, dried under a stream of N2, resolubilized in chloroform (120 μl), and 10 μl of this 
resolubilized lipid was injected onto an Agilent G6410B QQQ instrument. LC separation was 
achieved with a Gemini reverse-phase C18 column (5 μm, 4.6 mm x 50 mm, Phenomonex) 
together with a pre-column (C18, 3.5 μm, 2 mm x 20 mm). Mobile phase A was composed of a 
95:5 v/v H2O:MeOH, and mobile phase B was composed of a 65:35:5 v/v/v i-
PrOH:MeOH:H2O. 0.1% ammonium hydroxide was included to assist in ion formation in 
negative ionization mode and 0.1 % formic acid was included for positive ionization mode.   
The flow rate for each run started at 0.1 ml min–1 with 0% B. At 5 min, the solvent was 
immediately changed to 60% B with a flow rate of 0.4 ml min–1 and increased linearly to 
100%B over 10 min. This was followed by an isocratic gradient of 100% B for 5 min at 0.5 ml 
min–1 before equilibrating for 3 min at 0% B at 0.5 ml min–1 (23 min total per sample). The 
following MS parameters were used to measure the indicated metabolites (precursor ion, 
product ion,collision energy in V): AEA (348, 62, 11), OEA (326, 62, 11), PEA (300, 62, 11), 
2-AG (379, 287, 8), OG (357, 265, 8), PG (331, 239, 8), dodecylglycerol (261, 261, 0), 
pentadecanoic acid (241, 241, 0), arachidonic acid (303, 303, 0), PGE2 (351, 271, 10), PGD2 
(351, 271, 10), TXB2 (369,195,5), 5,6-EET (319,191,3). MS analysis was performed with an 
electrospray ionization (ESI) source. The dwell time for each lipid was set to 60 ms. The 
capillary was set to 4 kV, the fragmentor was set to 100 V, and the delta EMV was set to +300. 
The drying gas temperature was 350°C, the drying gas flow rate was 11 l min–1, and the 
nebulizer pressure was 35 psi. Lipids were quantified by measuring the area under the peak in 
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comparison to an external standard curve with MAGs, NAEs, or eicosanoids with the internal 
standards. 
Statistical Analysis 
All data are reported as mean ± SEM. AEA, arachidonic acid, PGE2 and 2-AG levels are 
reported as pmol or nmol per gram of tissue, where applicable. Data were analyzed using two-
way between measures analysis of variance (ANOVA), followed by Dunnett’s or Scheffe’s post 
hoc test. EFS contraction height was compared by paired t-test. Differences of p<0.05 were 
considered significant. 
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Results 
5.1. JZL184 and PF-3845 inhibit naloxone-precipitated isometric muscle contractions in 
morphine-dependent mouse ilea 
The effects of MAGL and FAAH inhibition were evaluated in an in vitro model of precipitated 
withdrawal in which mouse ileal longitudinal muscle is exposed to morphine (10 μM) for 60 
min and then naloxone (30 µM) was used to precipitate contractions. The height of naloxone-
precipitated contractions was been normalized to contractions elicited by 80 mM KCl.  JZL184 
(1 µM) attenuated naloxone-precipitated contractions in morphine-treated tissue [F(2,15) = 6.6; 
p <0.01; Fig. 24A]. However, rimonabant (100nM) did not reverse the attenuation of naloxone-
induced contractions by JZL184 (p = 0.73).  Representative traces of contraction before and 
after application of naloxone in the three conditions are shown in Fig. 24B.  In contrast, PF-
3845 (1 µM) attenuated the intensity of naloxone-precipitated contractions in a CB1 dependent 
manner, as indicated by a significant treatment effect [F(2,16) = 12.2; p < 0.001; Fig. 24C; see 
Fig. 24D for representative traces of contractions in the three conditions].  
5.2. JZL184 but not PF-3845 attenuates neurogenic field-stimulated contractions in naïve 
ileal tissue 
To investigate further, the impact of MAGL and FAAH inhibition on ileum function, we 
evaluated EFS cholinergic contractions in the longitudinal preparations from mouse ileum. 
These experiments were carried out in the absence of morphine and naloxone treatment to study 
whether the endocannabinoid catabolic enzyme inhibitors directly affected ileal contractility.  
The height of contractions was normalized to tissue weight and the height of contractions after 
drug treatment was normalized to percentage of pre-drug contraction for each tissue.  JZL184 
inhibited EFS contractions in the ileum (p<0.05), which was reversed by rimonabant [F(1,8) = 
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10.2; p < 0.05, Fig. 25C; Fig 23A for a representative trace].  In contrast, PF-3845 did not 
inhibit EFS contractions in the ileum (p = 0.36, Fig. 25C; Fig. 25B for a representative trace).  
5.3. Both JZL184 and PF-3845 inhibit naloxone-precipitated hypersecretion in morphine-
treated ilea 
Since both MAGL and FAAH inhibition reduces naloxone-precipitated hypercontractility, the 
effects of MAGL and FAAH inhibition was evaluated in an in vitro model of secretion in ileal 
tissue as measured by changes in short-circuit current (Isc). The measured current was 
normalized to the surface area of the tissue. Acute morphine treatment by itself caused a mild 
decrease in the Isc current. Naloxone exposure (30µM) to both CB1(+/+) and CB1(-/-) ileal tissue 
treated with morphine (30μM) for 60 min, resulted in a profound increase in Isc current (p<0.05 
v/s morphine control; Fig. 23A). The MAGL inhibitor JZL184 (10μM) and the FAAH inhibitor 
PF-3845 blocked naloxone-induced increase in Isc current in wild-type ileum tissue (p<0.05 v/s 
morphine-naloxone control; Fig. 26A and 26C). The anti-secretion effects of JZL184 were not 
observed in CB1(-/-) tissue (Fig. 26B). Taken together, these data suggest that both MAGL and 
FAAH inhibition attenuate naloxone-induced hypersecretion in morphine-dependent ileum 
tissue.  
5.4. Evaluation of effects of JZL184 on endocannabinoid, arachidonic acid and 
prostaglandin levels in ileum  
The data depicted in Fig. 24 and Fig. 25 suggest that FAAH inhibition attenuates ileal 
contractions during naloxone-precipitated withdrawal in a CB1 dependent manner, but does not 
directly affect ileal function in the absence of morphine. However, the finding that rimonabant 
did not block the reduction by JZL184 on naloxone precipitated contractions in morphine-
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dependent ilea (Fig. 24A), suggests a non-CB1 receptor mechanism. One mechanism by which 
JZL184 may inhibit naloxone-precipitated contractions is by altering arachidonic acid levels 
and prostaglandins.  It has been previously shown that genetic deletion or pharmacological 
inhibition of MAGL leads to a decrease in arachidonic acid levels in brain (Long et al., 2009a; 
Schlosburg et al., 2010). Because prostaglandins are a major product of arachidonic acid and 
also play a role in modulating neurogenic ileal contractions, we examined whether JZL184 
would alter levels of prostaglandin E2 and arachidonic acid as well as levels of AEA and 2-AG 
from ileal tissue.  Application of JZL184 (1 µM) to ileum in vitro did not significantly alter 2-
AG, AEA (table 5) or PGE2 (vehicle: 97.1 ± 12.1 pmol/g; JZL184: 99.8 ± 15.1 pmol/g), but 
inexplicably increased levels of arachidonic acid (p < 0.05; vehicle: 32.3 ± 3.0 nmol/g; JZL184 
66.3 ± 5.3 nmol/g). PF-3845 on the other hand elevated levels of AEA (table 5) but did not alter 
levels of 2-AG, AA or prostaglandins (data not shown). 
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Figure 24. Inhibitors of endocannabinoid catabolic enzymes reduced naloxone-precipitated 
contractions of morphine-treated ilea, as measured by isometric tension recording.   
 
(A) The MAGL inhibitor 
JZL184 (1 µM) attenuated 
the amplitude of naloxone-
precipitated contraction in 
ileum treated with 
morphine. Rimonabant 
(100nM) did not block the 
anti-withdrawal effects of 
JZL184. (B) 
Representative traces of 
contractions in each of the 
conditions before and after 
application of naloxone 
hydrochloride. 
(C) The FAAH inhibitor PF-3845 (1 µM) attenuated the amplitude of naloxone-precipitated 
contraction. Rimonabant (100nM) reversed the actions of PF-3845. (D) Representative traces of 
contractions in each of the conditions before and after application of naloxone hydrochloride. 
Data are expressed as mean ± SEM. ***p<0.001, * p<0.05 vs. morphine; ###p<0.001 vs. PF-
3845; n= 4-8 ilea/condition. 
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Figure 25: Evaluation of JZL184 and PF-3845 on field stimulated (EFS) contractions on 
longitudinal smooth muscle preparations from naïve ileum  
 
(A) Representative trace of 
EFS contractions before and 
after addition of JZL184 
(1µM). (B) Representative 
trace of EFS contractions 
before and after addition of 
PF-3845 (1µM). (C) 
Graphical representation of 
the amplitude of contractions 
represented as % of baseline 
values. JZL184 reduced the 
amplitude of EFS-stimulated 
contractions though the 
activation of CB1 receptors, 
but PF-3845 had no effect. 
Data expressed as mean ± 
SEM. *p<0.05, # p<0.05 vs. 
JZL184; n = 4-5 ilea/group. 
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Figure 26. Effects of MAGL and FAAH inhibition on naloxone-precipitated hypersecretion in 
CB1(+/+) and CB1(-/-) mice.  
(A) JZL184 blocks naloxone-precipitated hypersecretion in morphine-treated CB1(+/+) ileum 
tissue as measured by change in Isc current normalized to surface area. (B) JZL184 treatment 
does not alter naloxone-precipted hypersecretion in CB1(-/-) tissue (C) PF-3845 blocks 
naloxone-precipitated hypersecretion in morphine-treated C57BL6/J ileum. Data expressed as 
mean ± SEM. *p<0.05 v/s appropriate morphine control; #p<0.05 v/s corresponding morphine-
naloxone treated tissue. n=4-5 mice/ group; Data collected by Dr. Terez Shea-Donohue and Dr. 
Tim Vanuytsel at the University of Maryland, Baltimore 
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Table 5. Effects of FAAH and MAGL inhibitors on AEA and 2-AG levels in the ileum 
 Data expressed as mean ± SEM. n = 6 mice/group; *p < 0.05 vs. vehicle control. 
Treatment AEA pmol/g 2-AG nmol/g 
Vehicle 3.2 ± 0.5 13.2 ± 3.2 
PF-3845 (10 mg/kg) 7.9 ± 1.1* 8.8 ± 2.3 
JZL184 (40 mg/kg) 6.6 ± 1.6 19.5 ± 4.8 
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5.5. Discussion 
Based on the differential anti-diarrheal effects between JZL184 and PF-3845, we 
predicted a similar association on intestinal motility and secretion in in vitro models of 
naloxone-precipitated withdrawal in morphine-treated ilea. To test this hypothesis, we 
investigated the effects of endocannabinoid catabolic enzyme inhibitors in in vitro models of 
electrogenic mucosal ion transport and neurogenic contractions to account for the anti-diarrheal 
effects of MAGL inhibition. JZL184 attenuated the intensity of naloxone-precipitated ileal 
contractions, but rimonabant failed to reverse these effects, suggesting that these effects are 
non-CB1 mediated. Rimonabant blocked the effects of PF-3845 on naloxone-precipitated 
contractions in morphine-dependent ilea. Next, we demonstrated that naloxone can precipitate 
hypersecretion of electrolytes in morphine-dependent ileal tissue. In this model, effects of 
JZL184 in attenuating naloxone-precipitated hypersecretion in morphine-dependent ilea were 
abolished in CB1(-/-) mice suggesting that CB1 receptors modulate the anti-secretory actions of 
JZL184. 
Cannabinoid receptor agonists have been shown to inhibit the electric field stimulated 
(EFS) contractions of myenteric plexus-longitudinal muscle preparations through prejunctional 
CB1 receptors. This results in inhibition of contractile activity by blocking the release of 
acetylcholine from neurons of the myenteric plexus (Coutts and Pertwee, 1997). Acute exposure 
of ileal tissues to morphine also results in inhibition of EFS contractions via inhibition of Ach 
release (Paton, 1957). However, prolonged exposure leads to adaptations and naloxone can 
precipitate hypercontactility by inducing excess Ach release in these tissues (Tsou et al., 1982). 
Given the co-localization of MAGL, FAAH, CB1 receptors and opioid receptors in myenteric 
plexus (Bagnol et al., 1997; Coutts et al., 2002; MacNaughton et al., 2004; Bashashati et al., 
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2011), it is possible that both MAGL and FAAH inhibitors indirectly block hypercontractility 
during morphine withdrawal by attenuating the release of Ach from myenteric cholinergic 
neurons innervating the longitudinal muscle of the ileum. 
Acutely, opiates have anti-diarrheal effects by inducing constipation via inhibition of 
intestinal motility as well as electrolyte and fluid transport. Opiate withdrawal results in gastro-
intestinal distress including vomiting and diarrhea. Opiate agonists have been shown to have 
anti-secretory activity by affecting ion transport in the small intestine of mice (Sheldon et al., 
1990). Both MOR and DORs have been implicated in the anti-secretory actions of opiates. In 
our studies, we have shown that in vitro, these actions of opiates undergo adaptations on 
prolonged treatment. This study is first to show that naloxone precipitates a hypersecretory 
response in tissues treated with morphine for a prolonged period of time in the Ussing’s 
chamber. Cannabinoids also have been shown to have anti-secretory effects. The synthetic 
cannabinoid WIN blocks hypersecretion evoked by capsaicin or EFS in in vitro guinea pig and 
rat ileum preparations in the Ussing’s chamber in a CB1 dependent manner (Tyler et al., 2000; 
MacNaughton et al., 2004). These actions of cannabinoids are mediated by CB1 receptors in the 
submucosal plexus of the guinea pig ileum. JZL184 possibly exerts its effects indirectly via CB1 
receptors that are co-localized with MORs in the submucosal neurons (Maguma et al., 2010).  
The antecedents for diarrhea include enhanced contractility and increased secretion of 
fluids and electrolytes. Two observations from the present study indicate that the in vitro 
contraction model does not account for naloxone-precipitated diarrhea in morphine-dependent 
mice.  First, both JZL184 and PF-3845 attenuated naloxone-precipitated contractions in 
morphine-treated ilea in vitro, but only JZL184 blocked the occurrence of diarrhea in vivo.  
Second, rimonabant blocked the anti-diarrheal effects of JZL184 in vivo, but did not reduce 
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naloxone-precipitated contractions in ileum in vitro. Thus, while naloxone-precipitated 
contractions in morphine-treated ileum reflect a useful in vitro model of opioid withdrawal, this 
model does not account mechanistically for the autonomic withdrawal responses (i.e., diarrhea) 
observed in vivo. Additionally, both JZL184 and PF-3845 reversed naloxone-precipitated 
secretion in ileal tissue from CB1(+/+) and C57BL6/J mice, respectively. JZL184’s anti-
secretion effects were not observed in CB1(-/-) mice suggesting that CB1 receptors modulate the 
actions of MAGL inhibition in this model. The lack of agreement between the effects of these 
inhibitors in the in vitro model v/s the differential anti-diarrheal effects observed in vivo may be 
due to different antecedents in each of the studies. First, the length of exposure of morphine is 
only 1 h compared to 3 days in the behavioral assays. For secretion studies, female C57 mice 
served as subjects while in the in vivo studies ICR male mice were used. Finally, in the in vitro 
studies, exposure to various drugs was ex vivo in organ baths, while in vivo they were given 
systematically.  
Curiously, JZL184 did not increase 2-AG levels in ileum.  However, the effects of 
JZL184 in elevating 2-AG levels are tissue specific.  Likewise, JZL184 does not elevate 2-AG 
in other peripheral tissues, including testes, white adipose tissue, and lung, though it increases 
this endocannabinoid in other tissues, including liver, kidney, brown adipose tissue, and spleen 
(Long et al., 2009b).  MAGL blockade also reduces free arachidonic acid levels in brain (Long 
et al., 2009a), suggesting that the actions of JZL184 could be mediated in part by a blunting in 
the production of PGs and other eicosanoids. Additionally, JZL184’s anti-withdrawal effects in 
vivo as well as in the in vitro secretion model were reversed by rimonabant and in CB1 (-/-) mice 
respectively, implicating the involvement of CB1 receptors. JZL184 did not reduce levels of 
PGs in the ileum which corroborates with recent evidence that MAGL inhibition does not alter 
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AA and PG levels in gut (Nomura et al., 2011), which further argues against this alternative 
mechanism of action.  Therefore, it is possible in the present study that increases in 2-AG 
occurred in key synapses of enteric neurons obscured by bulk 2-AG in the whole tissue or that 
other enzymes regulate 2-AG in ileum, as has been observed for other non-neuronal cells/tissues 
(Marrs et al., 2010).   
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Chapter 6: Discussion 
Summary 
Previous studies have examined the ability of THC or exogenous cannabinoid agonists 
to reduce somatic opioid withdrawal signs in rodents. The purpose of the studies performed in 
this dissertation was to elucidate the potential of elevation of endocannabinoids, via inhibition 
of their degradative enzymes, to inhibit opioid withdrawal in pre-clinical rodent models of 
dependence. We hypothesized that elevating endogenous cannabinoids following inhibition of 
their appropriate catabolic enzymes would inhibit opioid withdrawal, through actions at 
cannabinoid receptors. Both MAGL and FAAH inhibition reduced both naloxone-precipitated 
as well as spontaneous somatic withdrawal signs with differential efficacy. Given the 
undesirable effects of prolonged complete MAGL inhibition and the reduced efficacy of FAAH 
inhibition to reduce somatic withdrawal signs compared to MAGL inhibition, we investigated a 
combination of partial MAGL and complete FAAH inhibition to maximize efficacy. This 
combination also reduced withdrawal signs without any associated dependence liability and 
mild receptor desensitization on repeated treatment. Finally, to elucidate the mechanism of anti-
diarrheal effects, we hypothesized that MAGL but not FAAH inhibition would block 
hypercontractility and hypersecretion in the ileum.  Both inhibitors blocked hypercontractility 
indicating that this model alone does not account for diarrhea. However MAGL inhibition 
significantly reduced withdrawal induced hypersecretion suggesting that MAGL inhibitors 
block diarrhea via anti-secretory actions. 
Differential effects of MAGL v/s FAAH inhibition 
Notably, high doses of JZL184 significantly blocked all opioid withdrawal symptoms, while 
PF-3845 only reduced a subset of these effects. Several explanations may account for the 
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differential effects of these enzyme inhibitors.  First, bulk brain levels of 2-AG are at least two 
orders of magnitude higher than AEA (Ahn et al., 2009; Long et al., 2009a), which was also the 
case in LC, PAG, and amygdala.  Thus, elevated 2-AG may achieve greater occupancy of brain 
CB1 receptors than AEA.  Second, 2-AG acts as a full CB1 receptor agonist, while AEA acts as 
a partial CB1 receptor agonist (Sugiura et al., 2002), suggesting that 2-AG produces greater 
intrinsic effects at the receptor than AEA.  Third, MAGL and FAAH are found in different 
neuronal populations and subcellular compartments, which could influence CB1 receptor 
signaling in the brain and result in distinct physiological functions for these endocannabinoids.  
For example, 2-AG drives short-term synaptic plasticity, while AEA is quiescent (Pan et al., 
2009).  Of course, it is possible that the efficacy of PF-3845 could be enhanced by increasing 
the drug pretreatment time or administering multiple injections of this FAAH inhibitor. Thus, 
comparison of results with JZL184 and PF-3845 suggests that AEA and 2-AG play different 
roles in modulating opiate withdrawal. 
Anti-withdrawal mechanism of action of MAGL and FAAH inhibition in vitro 
In addition to attenuating somatic withdrawal signs with a higher efficacy, MAGL inhibition 
also completely blocked occurrence of diarrhea in vivo, while FAAH inhibition lacked anti-
diarrheal efficacy. In order to understand the underlying mechanism, we examined the effects of 
both MAGL and FAAH inhibitors in in vitro assays of diarrhea. The precursors of diarrhea 
include enhanced contractility of the intestinal muscle (i.ie enhanced motility) as well as 
hypersecretion of water and electrolytes. Both JZL184 and PF-3845 reduced naloxone-
precipitated contractions and reduced hypersecretion in the ileum in a CB1-dependent manner. 
There are several mechanisms by which CB1 activation may modulate anti-secretory effects and 
block contractility. One possibility is that activation of CB1 receptors innervating cholinergic 
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secretomotoneurons (MacNaughton et al., 2004) may block Ach induced activation of transport 
proteins in the mucosa and submucosa (Fig 27). Additionally, CB1 activation in myenteric 
neurons may block acetylcholine mediated hypercontraction of longitudinal muscle. Thus, 
inhibitors of endocannabinoid catabolic enzymes attenuate opiate withdrawal effects in two 
distinct in vitro models in the small intestine. 
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Figure 27: Ant-diarrheal mechanism of action of MAGL and FAAH inhibitors in the ileum 
(Top) JZL184 and PF-3845 reduces mucosal hypersecretion in the ileum diarrhea through 
activation of CB1 receptors in the submucosal neurons (Bottom) Both JZL184 (non-CB1) and 
PF-3845 (via CB1) reduce naloxone-precipitated neurogenic contraction of the longitudinal 
muscle by affecting Ach release from myenteric neurons.  
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Advantages of MAGL and FAAH inhibitors over traditional cannabinoids 
While THC and other direct-acting CB1 receptor agonists elicit marijuana-like psychoactive 
effects, endocannabinoid catabolic inhibitors appear to possess fewer cannabimimetic effects 
than CB1 receptor agonists.  In particular, FAAH inhibitors do not substitute for THC in the 
drug discrimination paradigm, do not produce hypothermia, hypomotility, catalepsy or memory 
impairment, and lack reinforcing properties (Ahn et al., 2008).  While the MAGL inhibitor 
JZL184 produces a broader set of cannabinoid behavioral effects, including hypomotility, 
hypothermia and hyper-reflexia, than FAAH inhibitors, it does not cause the full spectrum of 
THC-like effects.  In particular, JZL184 does not substitute for THC in the drug discrimination 
paradigm and does not produce catalepsy (Long et al., 2009b; Long et al., 2009c).  In contrast, 
dual inhibitors of both FAAH and MAGL, such as JZL195, produce much greater THC-like 
effects, including catalepsy, increased antinociceptive efficacy, and substitution in the THC 
discrimination paradigm (Long et al., 2009c) than single enzyme inhibitors, underscoring the 
importance of maintaining selectivity for individual endocannabinoid pathways in the 
development of FAAH and MAGL inhibitors.  Moreover, sustained FAAH blockade does not 
alter CB1 receptor function and lacks dependence liability (Schlosburg et al., 2009; Schlosburg 
et al., 2010).  Additionally, the observation that FAAH (-/-) mice show an attenuated opioid 
withdrawal syndrome suggests that the anti-opioid withdrawal effects of FAAH inhibition 
persist even upon genetic deletion of FAAH.  
Advantages of combining partial MAGL and complete FAAH inhibition 
On the other hand, other studies indicate that complete MAGL inhibition may possess 
potential for rewarding effects and share other hallmarks in common with drugs of abuse. High 
dose JZL184 partially substitutes for THC in the drug discrimination paradigm (Long et al., 
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2009c).  In addition, repeated JZL184 elicits cannabinoid dependence, behavioral and functional 
tolerance, and cannabinoid receptor cross-tolerance (Long et al., 2009c; Schlosburg et al., 
2010). It should still, however, be noted that many of the cannabimimetic side-effects of 
JZL184 are comparatively low in intensity versus moderate to high doses of THC or marijuana. 
However, while MAGL inhibitors possess far more side-effects than FAAH inhibitors, they 
showed much higher efficacy than FAAH inhibitors in reducing opioid withdrawal symptoms. 
Taken together, these results suggest that while both FAAH and MAGL inhibitors individually 
represent promising targets for reducing opioid dependence, they also have limitations. In order 
to circumvent some of these drawbacks, we investigated whether a combination of partial 
MAGL inhibition and complete FAAH inhibition would achieve enhanced efficacy in attenuating 
opioid withdrawal signs, without the negative side-effects associated with complete MAGL 
inhibition. Partial MAGL inhibition is achieved with lower dose of JZL184 (4 mg/kg) that 
produces a physiologically relevant response by elevating 2-AG levels (2-4 fold). The 
combination of partial MAGL and complete FAAH inhibition elevates AEA levels similar to 
FAAH inhibition alone, but elevated 2-AG levels higher than that observed with MAGL 
inhibition alone in ICR mice. Thus, it is possible that the combination exerts beneficial anti-
withdrawal effects due to enhanced levels of 2-AG. Although this combination did not produce 
CB1 receptor down-regulation, it induced moderate CB1 desensitization following repeated 
treatment. In C57BL/6J mice, prolonged exposure to the combination did not induce any CB1 
receptor functional tolerance, analgesic tolerance in pain assays (Wise, Kinsey et al., 
unpublished data) or physical cannabinoid withdrawal. Taken together, the anti-withdrawal and 
analgesic effects of this combination coupled with its lack of dependence potential are 
important findings for the clinical development of a combined drug that is a partial MAGL and 
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a complete FAAH inhibitor. To this effect, a novel inhibitor SA-57 which has differential 
potency at MAGL and FAAH has been synthesized (Niphakis et al., 2011). The in vivo 
pharmacological actions of this inhibitor remains to be characterized. 
Anti-withdrawal mechanism of action: Brain 
Although determining the molecular mechanisms for endocannabinoid dampening of 
opioid withdrawal is beyond the scope of this dissertation, findings from previously published 
reports provide insight. A section of studies has suggested that opioid and cannabinoid receptors 
may interact due to their close proximal location within the neuron via signaling with a common 
G-protein pool, by forming functional heterodimers, or by allosterically modulating reciprocal 
functions (Rios et al., 2006; Hojo et al., 2008; Scavone et al., 2010). It is well established that 
acute morphine inhibits adenylyl cyclase at the cellular level, while opiate withdrawal leads to 
increased production of adenylyl cyclase and downstream signaling molecules in the LC and 
PAG (Nestler and Tallman, 1988; Guitart et al., 1992; Punch et al., 1997).  These signaling 
events are associated with the expression of somatic and autonomic behavioral withdrawal signs 
(Shaw-Lutchman et al., 2002). Thus, increasing endocannabinoid activity may counteract the 
consequences of cAMP overshoot during opioid withdrawal (Fig. 28)  This notion is consistent 
with the colocalization of CB1 and MOR in the LC and other brain regions as well as in the 
ileum (Maguma et al., 2010; Scavone et al., 2010).  The observations that acute CB1 receptor 
stimulation inhibits adenylyl cyclase and decreases cAMP production and that MOR and CB1 
receptors have been demonstrated in cell lines to share a common pool of adenylyl cyclase 
further supports this hypothesis (Howlett and Mukhopadhyay, 2000; Levitt et al., 2010).  The 
other less explored hypothesis is that CB1 may modulate signaling of MOR at the extra receptor 
level by altering signaling at the second messenger level (cAMP cascade, MAPK cascade or 
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Ca
2+
 signaling); affecting transcription of dependence induced genes or directly modulates 
release of neurotransmitters such as dopamine at the interneuronal level. Alternatively, CB1 
receptor activation is well known to reduce the release of GABA, glutamate, norepinephrine, 
and other neurotransmitters believed to be mediated through the inhibition of the adenylyl 
cyclase and the downstream mediators (Piomelli, 2003). Thus, dampening of other transmitters 
systems caused by CB1 receptor activation represents an alternative mechanism by which 
endogenous cannabinoids could reduce opioid withdrawal. 
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Figure 28: Proposed mechanism of action of anti-withdrawal effects of JZL184 in the brain 
(Clock-wise) Acute morphine treatment causes suppression of AC activity and its downstream 
effects; Chronic morphine exposure leads to upregulation of AC and normalization of 
downstream signaling; Induction of withdrawal following chronic morphine exposure causes 
cAMP “overshoot” and increasing signaling of cAMP cascade resulting in expression of 
withdrawal signs; Acute, indirect CB1 activation by JZL184 inhibits AC and its downstream 
cascade, thereby attenuating withdrawal. 
  
117 
 
Another important consideration is whether endocannabinoid catabolic enzymes inhibitors 
will affect other components of opioid addiction, such as drug reward, extinction, relapse, and 
craving. Nonetheless, the results from the present study are the first to show that elevation of 
endocannabinoid levels ameliorates the expression of opioid withdrawal. The preliminary in 
vitro and in vivo studies presented here establish that endocannabinoid catabolic enzymes may 
represent attractive targets to treat severe withdrawal signs associated with opioid dependence. 
These inhibitors offer advantages over current treatment options such as benzodiazepines, 
methadone, buprenorphine or naltrexone. These inhibitors produce selective elevation of eCBs, 
do not substitute for opioids as they do not have the same dependence liability and lack side-
effects of benzodiazepines and opiate substitutes. Additionally, cannabinoids and morphine act 
at similar brain regions and affect similar signal transduction pathways. Rather than 
management or symptomatic treatment of withdrawal signs, elevating endocannabinoids may 
mechanistically alleviate abstinence signs by directly acting on signaling machinery in brain 
areas associated with opiate dependence. Thus, the enzymes responsible for endocannabinoid 
degradation offer promising targets for possible new treatments for opioid dependence. 
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